Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 42
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Inhibition of ATP-citrate lyase by bempedoic acid protects against abdominal aortic aneurysm formation in mice

  • Puertas Umbert, Lídia|||0000-0002-2739-6522
  • Almendra-Pegueros, Rafael|||0000-0002-4411-4515
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Rodríguez Sinovas, Antonio|||0000-0003-2930-8773
  • Galán, María|||0000-0002-4758-8388
  • Roglans, Nuria
  • Laguna, Joan Carles|||0000-0002-2357-1186
  • Martínez-González, José|||0000-0002-3894-7166
  • Rodríguez, Cristina|||0000-0002-6472-5647
  • Alonso Nieto, Judith|||0000-0003-0537-0417
  • Blanco-Casoliva, Laia
Abdominal aortic aneurysm (AAA) is a prevalent degenerative disease characterized by an exacerbated inflammation and destructive vascular remodeling. Unfortunately, effective pharmacological tools for the treatment of this disease remain a challenge. ATP-citrate lyase (ACLY), the primary enzyme responsible for acetyl-CoA biosynthesis, is a key regulator of inflammatory signaling in macrophages and lymphocytes. Here, we found increased levels of the active (phosphorylated) form of ACLY (p-ACLY) in the inflammatory infiltrate of AAA from patients and in aneurysmal lesions from angiotensin II (Ang II)-infused apolipoprotein E-deficient mice (ApoE). Furthermore, plasma ACLY levels positively correlates with IL6 and IFNγ levels in patients with AAA, while inflammatory stimuli strongly upregulated ACLY expression in macrophages and Jurkat cells. The administration of the ACLY inhibitor bempedoic acid (BemA) protected against Ang II-induced AAA formation in ApoE mice, limiting the progression of aortic dilatation and reducing mortality due to aortic rupture. BMS-303141, another ACLY inhibitor, also ameliorated AAA formation, although to a lesser extent. BemA attenuated vascular remodeling and the disorganization and rupture of elastic fibers induced by Ang II, as well as vascular inflammation, decreasing the recruitment of macrophages (CD68 +) and neutrophils (Ly-6G+) into the aortic wall. Moreover, BemA shifted splenic monocytes toward a functionally anti-inflammatory phenotype, and increased the percentage of CD4CD69 cells. Taken together, these results support the contribution of ACLY to AAA and point to BemA as a promising tool to be considered for future clinical trials addressing the management of this disease which is quite often associated with disorders of lipoprotein metabolism.
Repisalud
Publicación Artículo científico (JournalArticle)

Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study

  • Ibáñez-Sanz, Gemma
  • Díez-Villanueva, Anna
  • Vilorio-Marqués, Laura
  • Gracia, Esther
  • Aragones, Nuria
  • Olmedo-Requena, Rocío
  • Llorca, Javier
  • Vidán, Juana
  • Amiano, Pilar
  • Nos, Pilar
  • Fernández-Tardón, Guillermo
  • Rada, Ricardo
  • Chirlaque, María-Dolores
  • Guinó, Elisabet
  • Dávila-Batista, Verónica
  • Castaño-Vinyals, Gemma
  • Perez-Gomez, Beatriz
  • Mirón-Pozo, Benito
  • Dierssen-Sotos, Trinidad
  • Etxeberria, Jaione
  • Molinuevo, Amaia
  • Álvarez-Cuenllas, Begoña
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Moreno, Victor
A safe and effective colorectal cancer (CRC) chemoprevention agent remains to be discovered. We aim to evaluate the association between the use of glucosamine and/or chondroitin sulphate and risk of colorectal cancer (CRC) in the MCC-Spain study, a case-control study performed in Spain that included 2140 cases of CRC and 3950 population controls. Subjects were interviewed on sociodemographic factors, lifestyle, family and medical history and regular drug use. Adjusted odds ratios and their 95% confidence intervals were estimated. The reported frequency of chondroitin and/or glucosamine use was 2.03% in controls and 0.89% in cases. Users had a reduced risk of CRC (OR: 0.47; 95% CI: 0.28-0.79), but it was no longer significant when adjusted for NSAID (nonsteroidal anti-inflammatory drugs) use (OR: 0.82; 95% CI: 0.47-1.40). A meta-analysis with previous studies suggested a protective effect, overall and stratified by NSAID use (OR: 0.77; 95% CI: 0.62-0.97). We have not found strong evidence of an independent preventive effect of CG on CRC in our population because the observed effects of our study could be attributed to NSAIDs concurrent use. These results merit further research due to the safety profile of these drugs.
Repisalud
Publicación Artículo científico (JournalArticle)

Helicobacter pylori Antibody Reactivities and Colorectal Cancer Risk in a Case-control Study in Spain

  • Fernandez de Larrea-Baz, Nerea
  • Michel, Angelika
  • Romero, Beatriz
  • Perez-Gomez, Beatriz
  • Moreno, Victor
  • Martín, Vicente
  • Dierssen-Sotos, Trinidad
  • Jimenez-Moleon, Jose J.
  • Castilla Catalán, Jesús
  • Tardón, Adonina
  • Ruiz, Irune
  • Peiró, Rosana
  • Tejada, Antonio
  • Chirlaque, María-Dolores
  • Butt, Julia A
  • Olmedo-Requena, Rocío
  • Gómez-Acebo, Inés
  • Linares, Pedro
  • Boldo, Elena
  • Castells, Antoni
  • Pawlita, Michael
  • Castaño-Vinyals, Gemma
  • Kogevinas, Manolis
  • de Sanjose, Silvia
  • Pollan-Santamaria, Marina
  • Del Campo, Rosa
  • Waterboer, Tim
  • Aragones, Nuria
Background: Several studies have suggested that Helicobacter pylori (H. pylori) infection is a risk factor for colorectal cancer (CRC), while others have not confirmed this hypothesis. This work aimed to assess the relation of CRC with H. pylori seropositivity and with seropositivity to 16 H. pylori proteins, in the MultiCase-Control study, MCC-Spain. Methods: MCC-Spain is a multicase-control study carried out in Spain from 2008 to 2013. In total, 2,140 histologically-confirmed incident CRC cases and 4,098 population-based controls were recruited. Controls were frequency-matched by sex, age, and province. Epidemiological data were collected through a questionnaire fulfilled by face-to-face interviews and a self-administered food-frequency questionnaire. Seroreactivities against 16 H. pylori proteins were determined in 1,488 cases and 2,495 controls using H. pylori multiplex serology. H. pylori seropositivity was defined as positivity to ≥4 proteins. Multivariable logistic regression mixed models were used to estimate odds ratios (OR) and 95% confidence intervals (CI). Results:H. pylori seropositivity was not associated with increased CRC risk (OR = 0.91; 95% CI: 0.71-1.16). Among H. pylori seropositive subjects, seropositivity to Cagδ showed a lower CRC risk, and risk decreased with increasing number of proteins seropositive. Seropositivity to the most recognized virulence factors, CagA and VacA, was not associated with a higher CRC risk. No statistically significant heterogeneity was identified among tumor sites, although inverse relations were stronger for left colon cancer. An interaction with age and sex was found: H. pylori seropositivity was associated with a lower CRC risk in men younger than 65 and with a higher risk in older women. Conclusions: Our results suggest that neither H. pylori seropositivity, nor seropositivity to the virulence factor CagA are associated with a higher CRC risk. A possible effect modification by age and sex was identified.
Repisalud
Publicación Artículo científico (JournalArticle)

Risk of breast cancer and residential proximity to industrial installations: New findings from a multicase-control study (MCC-Spain)

  • García-Pérez, Javier
  • Lope Carvajal, Virginia
  • Perez-Gomez, Beatriz
  • Molina, Antonio José
  • Tardón, Adonina
  • Díaz Santos, María Angustias
  • Ardanaz, Eva
  • O'Callaghan-Gordo, Cristina
  • Altzibar, Jone M
  • Gómez-Acebo, Inés
  • Moreno, Victor
  • Peiró, Rosana
  • Marcos-Gragera, Rafael
  • Kogevinas, Manolis
  • Aragones, Nuria
  • Lopez-Abente, Gonzalo
  • Pollan-Santamaria, Marina
Breast cancer is the most frequent tumor in women worldwide, although well-established risk factors account for 53%-55% of cases. Therefore, other risk factors, including environmental exposures, may explain the remaining variation. Our objective was to assess the relationship between risk of breast cancer and residential proximity to industries, according to categories of industrial groups and specific pollutants released, in the context of a population-based multicase-control study of incident cancer carried out in Spain (MCC-Spain). Using the current residence of cases and controls, this study was restricted to small administrative divisions, including both breast cancer cases (452) and controls (1511) in the 10 geographical areas recruiting breast cancer cases. Distances were calculated from the respective woman's residences to the 116 industries located in the study area. We used logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (95%CIs) for categories of distance (between 1 km and 3 km) to industrial plants, adjusting for matching variables and other confounders. Excess risk (OR; 95%CI) of breast cancer was found near industries overall (1.30; 1.00-1.69 at 3 km), particularly organic chemical industry (2.12; 1.20-3.76 at 2.5 km), food/beverage sector (1.87; 1.26-2.78 at 3 km), ceramic (4.71; 1.62-13.66 at 1.5 km), surface treatment with organic solvents (2.00; 1.23-3.24 at 3 km), and surface treatment of plastic and metals (1.51; 1.06-2.14 at 3 km). By pollutants, the excess risk (OR; 95%CI) was detected near industries releasing pesticides (2.09; 1.14-3.82 at 2 km), and dichloromethane (2.09; 1.28-3.40 at 3 km). Our results suggest a possible increased risk of breast cancer in women living near specific industrial plants and support the need for more detailed exposure assessment of certain agents released by these plants.
Repisalud
Publicación Artículo científico (JournalArticle)

Risk Model for Prostate Cancer Using Environmental and Genetic Factors in the Spanish Multi-Case-Control (MCC) Study

  • Gómez-Acebo, Inés
  • Dierssen-Sotos, Trinidad
  • Fernandez-Navarro, Pablo L
  • Palazuelos, Camilo
  • Moreno, Victor
  • Aragones, Nuria
  • Castaño-Vinyals, Gemma
  • Jimenez-Moleon, Jose J.
  • Ruiz-Cerdá, Jose Luis
  • Perez-Gomez, Beatriz
  • Ruiz-Dominguez, José Manuel
  • Molero, Jessica Alonso
  • Pollan-Santamaria, Marina
  • Kogevinas, Manolis
  • Llorca, Javier
Prostate cancer (PCa) is the second most common cancer among men worldwide. Its etiology remains largely unknown compared to other common cancers. We have developed a risk stratification model combining environmental factors with family history and genetic susceptibility. 818 PCa cases and 1,006 healthy controls were compared. Subjects were interviewed on major lifestyle factors and family history. Fifty-six PCa susceptibility SNPs were genotyped. Risk models based on logistic regression were developed to combine environmental factors, family history and a genetic risk score. In the whole model, compared with subjects with low risk (reference category, decile 1), those carrying an intermediate risk (decile 5) had a 265% increase in PCa risk (OR = 3.65, 95% CI 2.26 to 5.91). The genetic risk score had an area under the ROC curve (AUROC) of 0.66 (95% CI 0.63 to 0.68). When adding the environmental score and family history to the genetic risk score, the AUROC increased by 0.05, reaching 0.71 (95% CI 0.69 to 0.74). Genetic susceptibility has a stronger risk value of the prediction that modifiable risk factors. While the added value of each SNP is small, the combination of 56 SNPs adds to the predictive ability of the risk model.
Repisalud
Publicación Artículo científico (JournalArticle)

Mendelian randomization analysis rules out disylipidaemia as colorectal cancer cause

  • Ibáñez-Sanz, Gemma
  • Díez-Villanueva, Anna
  • Riera-Ponsati, Marina
  • Fernández-Villa, Tania
  • Fernandez-Navarro, Pablo L
  • Bustamante, Mariona
  • Llorca, Javier
  • Amiano, Pilar
  • Ascunce, Nieves
  • Fernández-Tardón, Guillermo
  • Salcedo Bellido, Inmaculada
  • Salas, Dolores
  • Capelo Álvarez, Rocío
  • Crous-Bou, Marta
  • Ortega-Valín, Luis
  • Perez-Gomez, Beatriz
  • Castaño-Vinyals, Gemma
  • Palazuelos, Camilo
  • Altzibar, Jone M
  • Ardanaz, Eva
  • Tardón, Adonina
  • Jimenez-Moleon, Jose J.
  • Olmos Juste, Valle
  • Aragones, Nuria
  • Pollan-Santamaria, Marina
  • Kogevinas, Manolis
  • Moreno, Victor
Dyslipidemia and statin use have been associated with colorectal cancer (CRC), but prospective studies have shown mixed results. We aimed to determine whether dyslipidemia is causally linked to CRC risk using a Mendelian randomization approach and to explore the association of statins with CRC. A case-control study was performed including 1336 CRC cases and 2744 controls (MCC-Spain). Subjects were administered an epidemiological questionnaire and were genotyped with an array which included polymorphisms associated with blood lipids levels, selected to avoid pleiotropy. Four genetic lipid scores specific for triglycerides (TG), high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), or total cholesterol (TC) were created as the count of risk alleles. The genetic lipid scores were not associated with CRC. The ORs per 10 risk alleles, were for TG 0.91 (95%CI: 0.72-1.16, p = 0.44), for HDL 1.14 (95%CI: 0.95-1.37, p = 0.16), for LDL 0.97 (95%CI: 0.81-1.16, p = 0.73), and for TC 0.98 (95%CI: 0.84-1.17, p = 0.88). The LDL and TC genetic risk scores were associated with statin use, but not the HDL or TG. Statin use, overall, was a non-significant protective factor for CRC (OR 0.84; 95%CI: 0.70-1.01, p = 0.060), but lipophilic statins were associated with a CRC risk reduction (OR 0.78; 95%CI 0.66-0.96, p = 0.018). Using the Mendelian randomization approach, our study does not support the hypothesis that lipid levels are associated with the risk of CRC. This study does not rule out, however, a possible protective effect of statins in CRC by a mechanism unrelated to lipid levels.
Repisalud
Publicación Artículo científico (JournalArticle)

Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study

  • Gómez-Acebo, Inés
  • Dierssen-Sotos, Trinidad
  • Mirones, Mónica
  • Perez-Gomez, Beatriz
  • Guevara, Marcela
  • Amiano, Pilar
  • Sala, María
  • Molina, Antonio J
  • Alonso-Molero, Jéssica
  • Moreno, Victor
  • Suarez-Calleja, Claudia
  • Molina-Barceló, Ana
  • Alguacil, Juan
  • Marcos-Gragera, Rafael
  • Fernández-Ortiz, María
  • Sanz-Guadarrama, Oscar
  • Castaño-Vinyals, Gemma
  • Gil-Majuelo, Leire
  • Moreno-Iribas, Conchi
  • Aragones, Nuria
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Llorca, Javier
The St Gallen Conference endorsed in 2013 a series of recommendations on early breast cancer treatment. The main purpose of this article is to ascertain the clinical factors associated with St Gallen-2013 recommendations accomplishment. A cohort of 1152 breast cancer cases diagnosed with pathological stage < 3 in Spain between 2008 and 2013 was begun and then followed-up until 2017/2018. Data on patient and tumour characteristics were obtained from medical records, as well as their first line treatment. First line treatments were classified in three categories, according on whether they included the main St Gallen-2013 recommendations, more than those recommended or less than those recommended. Multinomial logistic regression models were carried out to identify factors associated with this classification and Weibull regression models were used to find out the relationship between this classification and survival. About half of the patients were treated according to St Gallen recommendations; 21% were treated over what was recommended and 33% received less treatment than recommended. Factors associated with treatment over the recommendations were stage II (relative risk ratio [RRR] = 4.2, 2.9-5.9), cancer positive to either progesterone (RRR = 8.1, 4.4-14.9) or oestrogen receptors (RRR = 5.7, 3.0-11.0). Instead, factors associated with lower probability of treatment over the recommendations were age (RRR = 0.7 each 10 years, 0.6-0.8), poor differentiation (RRR = 0.09, 0.04-0.19), HER2 positive (RRR = 0.46, 0.26-0.81) and triple negative cancer (RRR = 0.03, 0.01-0.11). Patients treated less than what was recommended in St Gallen had cancers in stage 0 (RRR = 21.6, 7.2-64.5), poorly differentiated (RRR = 1.9, 1.2-2.9), HER2 positive (RRR = 3.4, 2.4-4.9) and luminal B-like subtype (RRR = 3.6, 2.6-5.1). Women over 65 years old had a higher probability of being treated less than what was recommended if they had luminal B-like, HER2 or triple negative cancer. Treatment over St Gallen was associated with younger women and less severe cancers, while treatment under St Gallen was associated with older women, more severe cancers and cancers expressing HER2 receptors.
Repisalud
Publicación Artículo científico (JournalArticle)

Dietary Constituents: Relationship with Breast Cancer Prognostic (MCC-SPAIN Follow-Up)

  • Dierssen-Sotos, Trinidad
  • Gómez-Acebo, Inés
  • Gutiérrez-Ruiz, Nuria
  • Aragones, Nuria
  • Amiano, Pilar
  • Molina de la Torre, Antonio José
  • Guevara, Marcela
  • Alonso-Molero, Jéssica
  • Obón-Santacana, Mireia
  • Fernández-Tardón, Guillermo
  • Molina-Barceló, Ana
  • Alguacil, Juan
  • Marcos-Gragera, Rafael
  • Rodríguez-Cundín, Paz
  • Castaño-Vinyals, Gemma
  • Canseco Fernandez, Rosario
  • Castilla Catalán, Jesús
  • Molinuevo, Amaia
  • Perez-Gomez, Beatriz
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Llorca, Javier
The aim of this study was to characterize the relationship between the intake of the major nutrients and prognosis in breast cancer. A cohort based on 1350 women with invasive (stage I-IV) breast cancer (BC) was followed up. Information about their dietary habits before diagnosis was collected using a semi-quantitative Food Frequency Questionnaire. Participants without FFQ or with implausible energy intake were excluded. The total amount consumed of each nutrient (Kcal/day) was divided into tertiles, considering as "high intakes" those above third tertile. The main effect studied was overall survival. Cox regression was used to assess the association between death and nutrient intake. During a median follow-up of 6.5 years, 171 deaths were observed. None of the nutrients analysed was associated with mortality in the whole sample. However, in normal-weight women (BMI 18.5-25 kg/m2) a high intake of carbohydrates (≥809 Kcal/day), specifically monosaccharides (≥468 Kcal/day), worsened prognostic compared to lowest (≤352 Kcal/day). Hazard Ratios (HRs) for increasing tertiles of intake were HR:2.22 95% CI (1.04 to 4.72) and HR:2.59 95% CI (1.04 to 6.48), respectively (p trend = 0.04)). Conversely, high intakes of polyunsaturated fats (≥135 Kcal/day) improved global survival (HR: 0.39 95% CI (0.15 to 1.02) p-trend = 0.05) compared to the lowest (≤92.8 kcal/day). In addition, a protective effect was found substituting 100 kcal of carbohydrates with 100 kcal of fats in normal-weight women (HR: 0.76 95% CI (0.59 to 0.98)). Likewise, in premenopausal women a high intake of fats (≥811 Kcal/day) showed a protective effect (HR:0.20 95% CI (0.04 to 0.98) p trend = 0.06). Finally, in Estrogen Receptors (ER) negative tumors, we found a protective effect of high intake of animal proteins (≥238 Kcal/day, HR: 0.24 95% CI (0.06 to 0.98). According to our results, menopausal status, BMI and ER status could play a role in the relationship between diet and BC survival and must be taken into account when studying the influence of different nutrients.
Repisalud
Publicación Artículo científico (JournalArticle)

Antibody responses to flagellin C and Streptococcus gallolyticus pilus proteins in colorectal cancer

  • Butt, Julia
  • Fernandez de Larrea-Baz, Nerea
  • Tjalsma, Harold
  • Roelofs, Rian
  • Kato, Ikuko
  • Martín, Vicente
  • Perez-Gomez, Beatriz
  • Moreno, Victor
  • Dierssen-Sotos, Trinidad
  • Castilla Catalán, Jesús
  • Fernández-Tardón, Guillermo
  • Amiano, Pilar
  • Salas, Dolores
  • Alguacil, Juan
  • Jimenez-Moleon, Jose J.
  • Huerta, José María
  • de Sanjose, Silvia
  • Del Campo, Rosa
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Pawlita, Michael
  • Waterboer, Tim
  • Boleij, Annemarie
  • Aragones, Nuria
Antibodies to Streptococcus gallolyticus subspecies gallolyticus (SGG) have been associated with colorectal cancer (CRC). Because SGG may correlate with impaired gut epithelia, we assessed the association of antibodies to bacterial flagellin C (FliC), a measure potentially related to this impairment, with CRC and the CRC-specific interaction with antibodies to SGG proteins. Antibodies to FliC and SGG pilus proteins Gallo2178 and Gallo2179 were measured in two independent studies, a combined study from Nijmegen and Detroit (93 CRC cases, 74 controls) and a replication data set including 576 cases and 576 controls from the Spanish multicenter multicase-control study (MCC-Spain). Logistic regression was applied to assess whether antibodies to FliC were associated with CRC and modified the association of antibodies to SGG proteins with CRC. Antibodies to FliC were associated with those to SGG Gallo2178 among CRC cases, resulting in an interaction in the association of antibodies to Gallo2178 with CRC (p = 0.007). This association was only present among individuals with high antibody responses to FliC (OR: 2.42, 95% CI: 1.45-4.06). In conclusion, our findings suggest that colorectal tumorigenesis could be accompanied by an impaired integrity of the epithelium that could result in associated increased antibody responses to bacterial proteins.
Repisalud
Publicación Artículo científico (JournalArticle)

Risk Model for Colorectal Cancer in Spanish Population Using Environmental and Genetic Factors: Results from the MCC-Spain study

  • Ibáñez-Sanz, Gemma
  • Díez-Villanueva, Anna
  • Alonso, María Henar
  • Rodríguez-Moranta, Francisco
  • Perez-Gomez, Beatriz
  • Bustamante, Mariona
  • Martín, Vicente
  • Llorca, Javier
  • Amiano, Pilar
  • Ardanaz, Eva
  • Tardón, Adonina
  • Jimenez-Moleon, Jose J.
  • Peiró, Rosana
  • Alguacil, Juan
  • Navarro Rivas, Carmen
  • Guinó, Elisabet
  • Binefa, Gemma
  • Fernandez-Navarro, Pablo L
  • Espinosa, Anna
  • Dávila-Batista, Verónica
  • Molina, Antonio José
  • Palazuelos, Camilo
  • Castaño-Vinyals, Gemma
  • Aragones, Nuria
  • Kogevinas, Manolis
  • Moreno, Victor
  • Pollan-Santamaria, Marina
Colorectal cancer (CRC) screening of the average risk population is only indicated according to age. We aim to elaborate a model to stratify the risk of CRC by incorporating environmental data and single nucleotide polymorphisms (SNP). The MCC-Spain case-control study included 1336 CRC cases and 2744 controls. Subjects were interviewed on lifestyle factors, family and medical history. Twenty-one CRC susceptibility SNPs were genotyped. The environmental risk model, which included alcohol consumption, obesity, physical activity, red meat and vegetable consumption, and nonsteroidal anti-inflammatory drug use, contributed to CRC with an average per factor OR of 1.36 (95% CI 1.27 to 1.45). Family history of CRC contributed an OR of 2.25 (95% CI 1.87 to 2.72), and each additional SNP contributed an OR of 1.07 (95% CI 1.04 to 1.10). The risk of subjects with more than 25 risk alleles (5th quintile) was 82% higher (OR 1.82, 95% CI 1.11 to 2.98) than subjects with less than 19 alleles (1st quintile). This risk model, with an AUROC curve of 0.63 (95% CI 0.60 to 0.66), could be useful to stratify individuals. Environmental factors had more weight than the genetic score, which should be considered to encourage patients to achieve a healthier lifestyle.
Repisalud
Publicación Artículo científico (JournalArticle)

Risk of prostate cancer in the proximity of industrial installations: A multicase-control study in Spain (MCC-Spain).

  • García-Pérez, Javier
  • Fernandez de Larrea-Baz, Nerea
  • Lope Carvajal, Virginia
  • Domínguez-Castillo, Alejandro
  • Espinosa, Ana
  • Dierssen-Sotos, Trinidad
  • Contreras-Llanes, Manuel
  • Sierra, Maria Angeles
  • Castaño-Vinyals, Gemma
  • Tardón, Adonina
  • Jiménez-Moleón, José J
  • Molina-Barceló, Ana
  • Aragonés, Nuria
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Perez-Gomez, Beatriz
Background: Prostate cancer (PC) is the second most frequent tumor in men worldwide; however, its etiology remains largely unknown, with the exception of age and family history. The wide variability in incidence/mortality across countries suggests a certain role for environmental exposures that has not yet been clarified. Objective: To evaluate the association between risk of PC (by clinical profile) and residential proximity to pollutant industrial installations (by industrial groups, groups of carcinogens, and specific pollutants released), within the context of a Spanish population-based multicase-control study of incident cancer (MCC-Spain). Methods: This study included 1186 controls and 234 PC cases, frequency matched by age and province of residence. Distances from participants' residences to the 58 industries located in the study area were calculated and categorized into "near" (considering different limits between ≤1 km and ≤ 3 km) or "far" (>3 km). Odds ratios (ORs) and 95 % confidence intervals (95%CIs) were estimated using mixed and multinomial logistic regression models, adjusted for potential confounders and matching variables. Results: No excess risk was detected near the overall industries, with ORs ranging from 0.66 (≤2 km) to 1.11 (≤1 km). However, positive associations (OR; 95%CI) were found, by industrial group, near (≤3 km) industries of ceramic (2.54; 1.28-5.07), food/beverage (2.18; 1.32-3.62), and disposal/recycling of animal waste (2.67; 1.12-6.37); and, by specific pollutant, near plants releasing fluorine (4.65; 1.45-14.91 at ≤1.5 km) and chlorine (5.21; 1.56-17.35 at ≤1 km). In contrast, inverse associations were detected near industries releasing ammonia, methane, dioxins+furans, polycyclic aromatic hydrocarbons, trichloroethylene, and vanadium to air. Conclusions: The results suggest no association between risk of PC and proximity to the overall industrial installations. However, some both positive and inverse associations were detected near certain industrial groups and industries emitting specific pollutants.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity

  • Costoya Sánchez, Alejandro
  • Moscoso Rial, Alexis
  • Silva Rodríguez, Jesús
  • Pontecorvo, Michael J.
  • Devous Sr., Michael D.
  • Aguiar Fernández, Pablo
  • Schöll, Michael
  • Grothe, Michel J.
Importance An increased tau positron emission tomography (PET) signal in the medial temporal lobe (MTL) has been observed in older individuals in the absence of amyloid-β (Aβ) pathology. Little is known about the longitudinal course of this condition, and its association with Alzheimer disease (AD) remains unclear. Objective To study the pathologic and clinical course of older individuals with PET-evidenced MTL tau deposition (TMTL+) in the absence of Aβ pathology (A−), and the association of this condition with the AD continuum. Design, Setting, and Participants A multicentric, observational, longitudinal cohort study was conducted using pooled data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), Harvard Aging Brain Study (HABS), and the AVID-A05 study, collected between July 2, 2015, and August 23, 2021. Participants in the ADNI, HABS, and AVID-A05 studies (N = 1093) with varying degrees of cognitive performance were deemed eligible if they had available tau PET, Aβ PET, and magnetic resonance imaging scans at baseline. Of these, 128 participants did not meet inclusion criteria based on Aβ PET and tau PET biomarker profiles (A+ TMTL−). Exposures Tau and Aβ PET, magnetic resonance imaging, cerebrospinal fluid biomarkers, and cognitive assessments. Main Outcomes and Measures Cross-sectional and longitudinal measures for tau and Aβ PET, cortical atrophy, cognitive scores, and core AD cerebrospinal fluid biomarkers (Aβ42/40 and tau phosphorylated at threonine 181 p-tau181 available in a subset). Results Among the 965 individuals included in the study, 503 were women (52.1%) and the mean (SD) age was 73.9 (8.1) years. A total of 51% of A− individuals and 78% of A+ participants had increased tau PET signal in the entorhinal cortex (TMTL+) compared with healthy younger (aged <39 years) controls. Compared with A− TMTL−, A− TMTL+ participants showed statistically significant, albeit moderate, longitudinal (mean [SD], 1.83 [0.84] years) tau PET increases that were largely limited to the temporal lobe, whereas those with A+ TMTL+ showed faster and more cortically widespread tau PET increases. In contrast to participants with A+ TMTL+, those with A− TMTL+ did not show any noticeable Aβ accumulation over follow-up (mean [SD], 2.36 [0.76] years). Complementary cerebrospinal fluid analysis confirmed longitudinal p-tau181 increases in A− TMTL+ in the absence of increased Aβ accumulation. Participants with A− TMTL+ had accelerated MTL atrophy, whereas those with A+ TMTL+ showed accelerated atrophy in widespread temporoparietal brain regions. Increased MTL tau PET uptake in A− individuals was associated with cognitive decline, but at a significantly slower rate compared with A+ TMTL+. Conclusions and Relevance In this study, individuals with A− TMTL+ exhibited progressive tau accumulation and neurodegeneration, but these processes were comparably slow, remained largely restricted to the MTL, were associated with only subtle changes in global cognitive performance, and were not accompanied by detectable accumulation of Aβ biomarkers. These data suggest that individuals with A− TMTL+ are not on a pathologic trajectory toward AD.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Partial volume correction in longitudinal tau PET studies: is it really needed?

  • Costoya Sánchez, Alejandro
  • Moscoso Rial, Alexis
  • Sobrino Moreiras, Tomás
  • Ruibal Morell, Álvaro
  • Grothe, Michel J.
  • Schöll, Michael L.
  • Silva Rodríguez, Jesús
  • Aguiar Fernández, Pablo
Background [18F]flortaucipir (FTP) tau PET quantification is known to be affected by non-specific binding in off-target regions. Although partial volume correction (PVC) techniques partially account for this effect, their inclusion may also introduce noise and variability into the quantification process. While the impact of these effects has been studied in cross-sectional designs, the benefits and drawbacks of PVC on longitudinal FTP studies is still under scrutiny. The aim of this work was to study the performance of the most common PVC techniques for longitudinal FTP imaging. Methods A cohort of 247 individuals from the Alzheimer's Disease Neuroimaging Initiative with concurrent baseline FTP-PET, amyloid-beta (Aβ) PET and structural MRI, as well as with follow-up FTP-PET and MRI were included in the study. FTP-PET scans were corrected for partial volume effects using Meltzer's, a simple and popular analytical PVC, and both the region-based voxel-wise (RBV) and the iterative Yang (iY) corrections. FTP SUVR values and their longitudinal rates of change were calculated for regions of interest (ROI) corresponding to Braak Areas I-VI, for a temporal meta-ROI and for regions typically displaying off-target FTP binding (caudate, putamen, pallidum, thalamus, choroid plexus, hemispheric white matter, cerebellar white matter, and cerebrospinal fluid). The longitudinal correlation between binding in off-target and target ROIs was analysed for the different PVCs. Additionally, group differences in longitudinal FTP SUVR rates of change between Aβ-negative (A-) and Aβ-positive (A+), and between cognitively unimpaired (CU) and cognitively impaired (CI) individuals, were studied. Finally, we compared the ability of different partial-volume-corrected baseline FTP SUVRs to predict longitudinal brain atrophy and cognitive decline. Results Among off-target ROIs, hemispheric white matter showed the highest correlation with longitudinal FTP SUVR rates from cortical target ROIs (R2=0.28–0.82), with CSF coming in second (R2=0.28–0.42). Application of voxel-wise PVC techniques minimized this correlation, with RBV performing best (R2=0.00–0.07 for hemispheric white matter). PVC also increased group differences between CU and CI individuals in FTP SUVR rates of change across all target regions, with RBV again performing best (No PVC: Cohen's d = 0.26–0.66; RBV: Cohen's d = 0.43–0.74). These improvements were not observed for differentiating A- from A+ groups. Additionally, voxel-wise PVC techniques strengthened the correlation between baseline FTP SUVR and longitudinal grey matter atrophy and cognitive decline. Conclusion Quantification of longitudinal FTP SUVR rates of change is affected by signal from off-target regions, especially the hemispheric white matter and the CSF. Voxel-wise PVC techniques significantly reduce this effect. PVC provided a significant but modest benefit for tasks involving the measurement of group-level longitudinal differences. These findings are particularly relevant for the estimations of sample sizes and analysis methodologies of longitudinal group studies.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Renovación de destinos litorales maduros a partir del patrimonio cultural: Plan Costa Blanca Cultura

  • Navalón-García, Rosario
  • Rico, Elisa
  • Navalón-García, Rosario|||/items/486e6475-aabe-4365-b25e-6455e4335fdd
  • Rico, Elisa|||/items/b77768ec-e2d3-4d39-8791-0396cc7998e0
El destino turístico Costa Blanca se caracteriza por la existencia de una amplia oferta turística y por su situación privilegiada respecto a los mercados potenciales de demanda. En la actualidad, ambas características no son suficientes para garantizar la competitividad de este espacio; en un contexto turístico enormemente dinámico en el que la diversidad de elementos de atracción y la imagen del destino puede incidir en la decisión de viaje de los turistas. Por ello, ante la necesidad de acometer procesos de renovación del destino Costa Blanca que permitan garantizar la competitividad de la actividad en términos territoriales y económicos, se apuesta por el patrimonio cultural como uno de los argumentos que mayores posibilidades puede ofrecer desde el ámbito de la planificación del destino turístico para diseñar y ejecutar actuaciones encaminadas a la renovación del mismo. Así, la presente comunicación se basa en los principales resultados obtenidos en el Plan Costa Blanca Cultura, con el objetivo de analizar el grado de uso turístico del patrimonio cultural de la provincia de Alicante, para a partir de un diagnóstico previo, proponer estrategias y actuaciones encaminadas al diseño y gestión posterior de productos temáticos de naturaleza cultural. La metodología de trabajo se ha basado entre otras acciones, en la participación de los agentes turísticos y sociales, aspecto que ha llevado a la selección de las líneas de trabajo prioritarias basadas en temas que superarían la dicotomía entre litoral e interior otorgando al patrimonio un papel integrador del territorio, y a la propuesta de un modelo de gestión innovador en el destino Costa Blanca.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Renovación de destinos turísticos maduros, expertos y grupos de interés, discurso global-local y escenarios de futuro: el caso de Benidorm, Renovation of mature tourist destinations, experts and stakeholders, global-local discourses and future scenarios: the case of Benidorm

  • Rodriguez-Sanchez, Isabel
  • Conejero Quiles, Ana María
En este estudio se ha llevado a cabo una aproximación cualitativa a los discursos producidos por expertos y stakeholders locales de un destino maduro como Benidorm sobre aspectos clave vinculados a los conceptos de madurez y renovación de destinos turísticos. Se ha tratado de establecer una clarificación conceptual de los términos a partir de la opinión de los expertos y contrastar los principios teóricos obtenidos con la percepción de dos grupos de interés locales: empresarios turísticos y responsables de la gestión turística. Así, desde una doble vertiente, teórica y práctica, se aborda en este artículo el concepto de la renovación de destinos maduros.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

El potencial de los parques naturales en el proceso de renovación de los destinos turísticos litorales maduros: el caso de la Comunidad Valenciana en España, Exploring the potential naturals parks in the process of renovation of mature coastal tourist destinations: evidence from the Valencia Region in Spain

  • Capdepón Frías, Margarita
  • Rodriguez-Sanchez, Isabel
  • Such Climent, María Paz
  • Capdepón Frías, Margarita|||/items/34b1b202-ffb2-45d7-a1fe-acb13e9bfaab
  • Such Climent, María Paz|||/items/ce826b38-3d76-4feb-a65b-a7d2b77f19b7
La renovación de los destinos litorales, afectados por la indiferenciación y el agotamiento de su oferta, es un tema de plena actualidad del que depende la viabilidad futura de una actividad de gran importancia socioeconómica, por lo que el análisis de posibles estrategias dirigidas a mejorar dicha oferta resulta de gran relevancia. A tenor de este planteamiento, el presente estudio hace hincapié en el uso del patrimonio natural para la creación de productos turísticos en los destinos consolidados valencianos a partir de la revalorización de sus parques naturales. Para ello se han analizado otras experiencias donde los Espacios Naturales Protegidos (en adelante, ENP) se han incorporado en los procesos de renovación de algunos de los principales destinos maduros del litoral español. Por último, se ha valorado la potencialidad de los Parques Naturales litorales de la Comunidad Valenciana, contrastada con los responsables de su gestión. El trabajo ha servido, por una parte, para sopesar la predisposición de la Administración Pública ambiental respecto a un mejor uso de los parques naturales con fines turísticos y, por otra, para conocer la opinión de los gestores acerca de su actual grado de utilización. El texto concluye que los Parques Naturales de la Comunidad Valenciana poseen un notable patrimonio natural y cultural hasta ahora subestimado, y cuyo potencial se hace necesario considerar; y que si bien estos espacios presentan un aprovechamiento todavía limitado, sí existe un creciente desarrollo de actividades recreativas que complementan la tradicional oferta turística de los destinos litorales.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

El sistema de zonas húmedas del sur de Alicante (SZHSA). Del total desconocimiento a los peligros de su revalorización

  • Capdepón Frías, Margarita
  • Capdepón Frías, Margarita|||/items/34b1b202-ffb2-45d7-a1fe-acb13e9bfaab
Con el presente trabajo se pretende hacer un diagnóstico sobre el estado de los humedales costeros del sudeste peninsular y, en concreto, del Sistema de Zonas Húmedas del Sur de Alicante (SZHSA), así como conocer las interrelaciones que se producen con su correspondiente contexto territorial. Para ello, se ha obtenido información a través de fuentes directas e indirectas, y se ha elaborado una cartografía que servirá de soporte gráfico. En breve síntesis, las principales conclusiones indican que el SZHSA sigue soportando fuertes tensiones turísticas y urbanísticas a pesar de contar con un elevado grado de protección medioambiental. No obstante, en los últimos años se han desarrollado algunas propuestas para poner en valor recursos de componente natural para crear nuevas actividades y productos con los que diversificar la oferta turística, aunque con resultados variables y no siempre positivos.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

La reestructuración de los destinos consolidados del litoral castellonense: el caso de Benicàssim (Castellón, Comunitat Valenciana)

  • López Olivares, Diego
  • Ferreres Bonfill, Juan Bautista
Los cambios detectados en los hábitos de la demanda, la cual es cada vez más exigente con el destino turístico en su dimensión global y turística, obliga a reestructurar y en algunos casos a reinventar los destinos turísticos consolidados para que éstos sean sostenibles y competitivos. Este es el caso de los destinos turísticos del litoral castellonense, que se encuentran en diferentes generaciones de estrategias de cambio. Unos en etapa de renovación propia de la década de los ochenta; otros en estrategias de singularización, con la creación y diferenciación de producto, propia de los años noventa; y algunos realizando acciones de sostenibilidad en torno al patrimonio natural y cultural. En cualquier caso siguen necesitados de renovación, corrección de déficits urbanos, mejora de su imagen, etc. En esta comunicación tratamos de abordar estas problemáticas en los destinos litorales castellonenses, analizando las acciones realizadas en esos destinos y proponiendo estrategias de renovación en especial del destino turístico de Benicàssim, el cual es objeto de estudio en el marco del Proyecto “Renovestur” (Plan Nacional de I+D+i 2008-2011), realizado por el Instituto Universitario de Investigaciones Turísticas de la Universidad de Alicante. Proyecto del cual somos partícipes.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

El ciclo de vida de dos destinos de sol y playa consolidados del sur de Brasil: un primer acercamiento a Florianópolis y Balneario Camboriú

  • Soares, Jennifer Caroline
  • Gândara, José Manoel
Florianópolis y Balneario Camboriú son los dos principales destinos turísticos de sol y playa del sur de Brasil, con gran oferta de atractivos, equipamientos y servicios, y reconocidos como polos turísticos consolidados que atraen importantes flujos nacionales e internacionales. Aunque los dos destinos se consideren consolidados es necesario analizar en qué fase del ciclo de vida están para que puedan implementar medidas adecuadas de renovación. El objetivo de este trabajo consiste en presentar un análisis del ciclo de vida de dichos destinos, con la intención de identificar la evolución de ambos y compararlos. Como metodología, en primer lugar se realizó una investigación bibliográfica para identificar indicadores adicionales al modelo tradicional de análisis del ciclo de vida de los destinos; posteriormente, a través de una investigación documental, se han obtenido los datos de los destinos en publicaciones de organismos oficiales del Estado de Santa Catarina y brasileños. Las principales conclusiones del análisis del número de turistas se pudo observar que el Balneario Camboriú parece haber alcanzado la fase de estancamiento, mientras que Florianópolis parece estar en la fase de consolidación. En relación a los indicadores adicionales: ambos tienen como principal mercado emisor internacional Argentina, pero a la vez se está consolidando el mercado nacional; no se observa la dependencia de turoperadores; es problema principal es la gran presencia de turismo residencial en ambos, más acentuado en Balneario Camboriú; como también la gran dependencia económica de la actividad turística que existe en Balneario Camboriú. La relevancia o principal contribución de este estudio en relación a los anteriores, radica en los dos siguientes aspectos: primero, realizar una comparación entre dos destinos consolidados que comparten muchas características y que están sujetos a las mismas fuerzas externas; y segundo, un análisis del ciclo de vida basado en los conceptos relacionados al modelo de Butler, pero utilizando además otros indicadores complementarios identificados en la discusión teórica.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Consideraciones a propósito de una propuesta de indicadores de renovación de destinos turísticos maduros de sol y playa

  • Such Climent, María Paz
  • Rodriguez-Sanchez, Isabel
  • Such Climent, María Paz|||/items/ce826b38-3d76-4feb-a65b-a7d2b77f19b7
La situación actual de los destinos maduros de sol y playa impulsa la aplicación de instrumentos como el desarrollo de indicadores para tutelar el proceso de renovación. Con este propósito, del manejo de fuentes de información primarias, incluyendo un examen de las aportaciones vertidas en la bibliografía así como de los discursos de expertos acerca del tema de la renovación, se ha hecho una propuesta provisional de indicadores. No obstante, las limitaciones advertidas pueden dificultar su viabilidad.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Differential response to donepezil in MRI subtypes of mild cognitive impairment

  • Diaz-Galván, Patricia
  • Lorenzon, Giulia
  • Mohanty, Rosaleena
  • Mårtensson, Gustav
  • Cavedo, Enrica
  • Lista, Simone
  • Vergallo, Andrea
  • Kantarci, Kejal
  • Hampel, Harald
  • Dubois, Bruno
  • Grothe, Michel J.
  • Ferreira, Daniel
  • Westman, Eric
© The Author(s) 2023, corrected publication 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data., [Background] Donepezil is an approved therapy for the treatment of Alzheimer’s disease (AD). Results across clinical trials have been inconsistent, which may be explained by design-methodological issues, the pathophysiological heterogeneity of AD, and diversity of included study participants. We investigated whether response to donepezil differs in mild cognitive impaired (MCI) individuals demonstrating different magnetic resonance imaging (MRI) subtypes., [Methods] From the Hippocampus Study double-blind, randomized clinical trial, we included 173 MCI individuals (donepezil = 83; placebo = 90) with structural MRI data, at baseline and at clinical follow-up assessments (6–12-month). Efficacy outcomes were the annualized percentage change (APC) in hippocampal, ventricular, and total grey matter volumes, as well as in the AD cortical thickness signature. Participants were classified into MRI subtypes as typical AD, limbic-predominant, hippocampal-sparing, or minimal atrophy at baseline. We primarily applied a subtyping approach based on continuous scale of two subtyping dimensions. We also used the conventional categorical subtyping approach for comparison., [Results] Donepezil-treated MCI individuals showed slower atrophy rates compared to the placebo group, but only if they belonged to the minimal atrophy or hippocampal-sparing subtypes. Importantly, only the continuous subtyping approach, but not the conventional categorical approach, captured this differential response., [Conclusions] Our data suggest that individuals with MCI, with hippocampal-sparing or minimal atrophy subtype, may have improved benefit from donepezil, as compared with MCI individuals with typical or limbic-predominant patterns of atrophy. The newly proposed continuous subtyping approach may have advantages compared to the conventional categorical approach. Future research is warranted to demonstrate the potential of subtype stratification for disease prognosis and response to treatment., [Trial registration] ClinicalTrial.gov NCT00403520. Submission Date: November 21, 2006., Open access funding provided by Karolinska Institute. This study was funded by the Swedish Foundation for Strategic Research (SSF); the Strategic Research Programme in Neuroscience at Karolinska Institutet (StratNeuro); the Swedish Research Council (VR); the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet; Center for Innovative Medicine (CIMED); the Swedish Alzheimer Foundation; the Swedish Brain Foundation; King Gustaf V:s and Queen Victorias Foundation; Demensfonden; Stiftelsen Olle Engkvist Byggmästare; Birgitta och Sten Westerberg; Foundation for Geriatric Diseases at Karolinska Institutet; Loo och Hans Ostermans stiftelse för medicinsk forskning; Stiftelsen För Gamla Tjänarinnor; Gun & Bertil Stohnes Stiftelse. MJG is supported by the “Miguel Servet” programme [CP19/00031] and a research grant [PI20/00613] of the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER), National Institutes of Health, USA (U01 NS100620, P50 AG16574)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

How can I assess my patients with Parkinson's disease during a busy clinic day?

  • Cubo, Esther
  • García-Bustillo, Álvaro
  • Calvo, Sara
  • Gámez-Leyva, Gonzalo
  • Simón-Vicente, Lucia
  • Rivadeneyra, Jessica
  • Miranda, Javier
  • Madrigal, Elisabet
  • Martínez-Martín, Pablo
  • Mir, Pablo
  • Santos-García, Diego
  • COPPADIS Study Group
[Background] The evaluation of motor impairment in Parkinson's disease (PD) is mainly assessed with the motor subdomain of the Unified Parkinson's Disease Rating scale (UPDRS part III) and, lately, with the MDS-UPDRS part III. To optimize efforts and special needs during specific circumstances in clinical practice, we sought to identify the most sensitive items to assess motor impairment in PD., [Methods] We included the COPPADIS-PD cohort and collected the UPDRS part III at baseline (V0), 12 months (V1), and 24 months (V2). Factor analysis and effect size using Cohen's d formula were performed in the Off and On states at V0, V1, and V2., [Results] We included 667 patients with PD, mean age of 62.59 ± 8.91 years, 410 (60.2%) males, with a median HY stage of 2.00 (1.00; 4.00) at baseline. Over time, the most discriminating items were postural stability and body bradykinesia (“arise from chair” and “gait”) in the Off state, right and left upper extremity bradykinesia ("finger tap", "hand movements" and "prono/supination") in the On state. Body bradykinesia and right-left finger tapping were the items with the largest effect size (0.93, 0.84, 0.83, respectively) to assess motor improvement after receiving antiparkinsonian medications over time., [Conclusion] Under specific circumstances, selecting a few items of the UPDRS part III, including postural stability, body bradykinesia, and upper extremity bradykinesia, could be used to create a quick clinical judgment of motor status and improvement in PD., This work was supported by the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI20/00613], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], the Fundación Alicia Koplowitz and the Fundación "Curemos el Parkinson"., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Increased basal forebrain volumes could prevent cognitive decline in LRRK2 Parkinson's disease

  • Batzu, Lucia
  • Urso, Daniele
  • Grothe, Michel J.
  • Veréb, Dániel
  • Chaudhuri, K. Ray
  • Pereira, Joana B.
© 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)., [Background and objectives] It has been recently suggested that LRRK2 mutations are associated with a more benign clinical phenotype and a potentially more preserved cholinergic function in Parkinson's disease (PD). However, to our knowledge, no studies have tested whether the better clinical progression observed in LRRK2-PD patients is associated with more preserved volumes of a cholinergic brain area, the basal forebrain (BF). To address this hypothesis, here we compared BF volumes in LRRK2 carriers with and without PD with respect to idiopathic PD (iPD) patients and controls, and assessed whether they are associated with better clinical progression observed in LRRK2-PD compared to iPD., [Methods] Thirty-one symptomatic LRRK2-PD patients and 13 asymptomatic LRRK2 individuals were included from the Parkinson's Progression Markers Initiative. In addition, 31 patients with iPD and 13 healthy controls matched to the previous groups were also included. BF volumes were automatically extracted from baseline T1-weighted MRI scans using a stereotactic atlas of cholinergic nuclei. These volumes were then compared between groups and their relationship with longitudinal cognitive changes was evaluated using linear mixed effects models. Mediation analyses assessed whether BF volumes mediated differences in cognitive trajectories between groups., [Results] LRRK2-PD patients showed significantly higher BF volumes compared to iPD (P = 0.019) as did asymptomatic LRRK2 subjects compared to controls (P = 0.008). There were no other significant differences in cortical regions or subcortical volumes between these groups. BF volumes predicted longitudinal decline in several cognitive functions in iPD patients but not in LRRK2-PD, who did not show cognitive changes over a 4-year follow-up period. BF volumes were a significant mediator of the different cognitive trajectories between iPD and LRRK2-PD patients (95% CI 0.056–2.955)., [Discussion] Our findings suggest that mutations in LRRK2 are associated with increased BF volumes, potentially reflecting a compensatory hypercholinergic state that could prevent cognitive decline in LRRK2-PD patients., M.J.G. is supported by the “Miguel Servet” program [CP19/00031] and a research grant [PI20/00613] of the Instituto de Salud Carlos III – Fondo Europeo de Desarrollo Regional (ISCIII-FEDER). J.B.P. is supported by the Swedish Research Council (#2018–02201), The Center for Medical Innovation (#20200695), a Senior Researcher Faculty Position grant at Karolinska Institute grant, NeurotechEU, Alzheimerfonden, Gamla Tjänarinnor, Demensfonden and Stohnes., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity

  • Costoya-Sánchez, Alejandro
  • Moscoso, Alexis
  • Silva-Rodríguez, Jesús
  • Pontecorvo, Michael J.
  • Devous, Michael D.
  • Aguiar, Pablo
  • Schöll, Michael
  • Grothe, Michel J.
  • Alzheimer’s Disease Neuroimaging Initiative and the Harvard Aging Brain Study
© 2023 Costoya-Sánchez A et al. JAMA Neurology. This is an open access article distributed under the terms of the CC-BY License., [Importance] An increased tau positron emission tomography (PET) signal in the medial temporal lobe (MTL) has been observed in older individuals in the absence of amyloid-β (Aβ) pathology. Little is known about the longitudinal course of this condition, and its association with Alzheimer disease (AD) remains unclear., [Objective] To study the pathologic and clinical course of older individuals with PET-evidenced MTL tau deposition (TMTL+) in the absence of Aβ pathology (A−), and the association of this condition with the AD continuum., [Design, Setting, and Participants] A multicentric, observational, longitudinal cohort study was conducted using pooled data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), Harvard Aging Brain Study (HABS), and the AVID-A05 study, collected between July 2, 2015, and August 23, 2021. Participants in the ADNI, HABS, and AVID-A05 studies (N = 1093) with varying degrees of cognitive performance were deemed eligible if they had available tau PET, Aβ PET, and magnetic resonance imaging scans at baseline. Of these, 128 participants did not meet inclusion criteria based on Aβ PET and tau PET biomarker profiles (A+ TMTL−)., [Exposures] Tau and Aβ PET, magnetic resonance imaging, cerebrospinal fluid biomarkers, and cognitive assessments., [Main Outcomes and Measures] Cross-sectional and longitudinal measures for tau and Aβ PET, cortical atrophy, cognitive scores, and core AD cerebrospinal fluid biomarkers (Aβ42/40 and tau phosphorylated at threonine 181 p-tau181 available in a subset)., [Results] Among the 965 individuals included in the study, 503 were women (52.1%) and the mean (SD) age was 73.9 (8.1) years. A total of 51% of A− individuals and 78% of A+ participants had increased tau PET signal in the entorhinal cortex (TMTL+) compared with healthy younger (aged <39 years) controls. Compared with A− TMTL−, A− TMTL+ participants showed statistically significant, albeit moderate, longitudinal (mean [SD], 1.83 [0.84] years) tau PET increases that were largely limited to the temporal lobe, whereas those with A+ TMTL+ showed faster and more cortically widespread tau PET increases. In contrast to participants with A+ TMTL+, those with A− TMTL+ did not show any noticeable Aβ accumulation over follow-up (mean [SD], 2.36 [0.76] years). Complementary cerebrospinal fluid analysis confirmed longitudinal p-tau181 increases in A− TMTL+ in the absence of increased Aβ accumulation. Participants with A− TMTL+ had accelerated MTL atrophy, whereas those with A+ TMTL+ showed accelerated atrophy in widespread temporoparietal brain regions. Increased MTL tau PET uptake in A− individuals was associated with cognitive decline, but at a significantly slower rate compared with A+ TMTL+., [Conclusions and Relevance] In this study, individuals with A− TMTL+ exhibited progressive tau accumulation and neurodegeneration, but these processes were comparably slow, remained largely restricted to the MTL, were associated with only subtle changes in global cognitive performance, and were not accompanied by detectable accumulation of Aβ biomarkers. These data suggest that individuals with A− TMTL+ are not on a pathologic trajectory toward AD., We thank AVID Radiopharmaceuticals for supporting this study by facilitating access to the AVID-A05 data. The project that gave rise to these results received the support of a fellowship from la Caixa Foundation (ID 100010434). The fellowship code is LCF/BQ/DR20/11790012. Dr Aguiar and Mr Costoya-Sánchez are supported by the research grant PI9/01315 of the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) and by the Centro de Investigaciones Biomédicas en Red (CIBER, CB22/05/00067). Dr Grothe is supported by the Miguel Servet program (CP19/00031) and research grant PI20/00613 of the ISCIII-FEDER. Dr. Silva-Rodríguez is supported by the “Sara Borrell” program (CD21/00067) of the ISCIII-FEDER. Dr Schöll is supported by the Knut and Alice Wallenberg Foundation (Wallenberg Centre for Molecular and Translational Medicine; KAW2014.0363 and KAW 2023.0371), the Swedish Research Council (2017-02869, 2021-02678 and 2021-06545), the European Union’s Horizon Europe research and innovation program under grant agreement no 101132933 (AD-RIDDLE), the National Institute of Health (R01 AG081394-01), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (ALFGBG-813971 and ALFGBG-965326), the Swedish Brain Foundation (FO2021-0311) and the Swedish Alzheimer Foundation (AF-740191). Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health grant U01 AG024904) and Department of Defense ADNI (award W81XWH-12-2-0012). The ADNI is funded by the National Institute on Aging, and the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, Araclon Biotech, BioClinica Inc, Biogen, Bristol-Myers Squibb Company, CereSpir Inc, Cogstate, Eisai Inc, Elan Pharmaceuticals Inc, Eli Lilly and Company, EuroImmun, F. Hoffmann-La Roche Ltd and its affiliated company Genentech Inc, Fujirebio, GE Healthcare, IXICO Ltd, Janssen Alzheimer Immunotherapy Research & Development LLC, Johnson & Johnson Pharmaceutical Research & Development LLC, Lumosity, Lundbeck, Merck & Co Inc, Meso Scale Diagnostics LLC, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corp, Pfizer Inc, Piramal Imaging, Servier, Takeda Pharmaceutical Company, and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

LATE-NC staging in routine neuropathologic diagnosis: an update

  • Nelson, Peter T.
  • Lee, Edward B.
  • Cykowski, Matthew D.
  • Alafuzoff, Irina
  • Arfanakis, Konstantinos
  • Attems, Johannes
  • Brayne, Carol
  • Corrada, Maria M.
  • Dugger, Brittany N.
  • Flanagan, Margaret E.
  • Ghetti, Bernardino
  • Grinberg, Lea T.
  • Grossman, Murray
  • Grothe, Michel J.
  • Halliday, Glenda M.
  • Hasegawa, Masato
  • Hokkanen, Suvi R. K.
  • Hunter, Sally
  • Jellinger, Kurt
  • Kawas, Claudia H.
  • Keene, C. Dirk
  • Kouri, Naomi
  • Kovacs, Gabor G.
  • Leverenz, James B.
  • Latimer, Caitlin S.
  • Mackenzie, Ian R.
  • Mao, Qinwen
  • McAleese, Kirsty E.
  • Merrick, Richard
  • Montine, Thomas J.
  • Murray, Melissa E.
  • Myllykangas, Liisa
  • Nag, Sukriti
  • Neltner, Janna H.
  • Newell, Kathy L.
  • Rissman, Robert A.
  • Saito, Yuko
  • Sajjadi, S. Ahmad
  • Schwetye, Katherine E.
  • Teich, Andrew F.
  • Thal, Dietmar R.
  • Tomé, Sandra O.
  • Troncoso, Juan C.
  • Wang, Shih-Hsiu J.
  • White III, Charles L.
  • Wisniewski, Thomas
  • Yang, Hyun-Sik
  • Schneider, Julie A.
  • Dickson, Dennis W.
  • Neumann, Manuela
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/., An international consensus report in 2019 recommended a classification system for limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes (LATE-NC). The suggested neuropathologic staging system and nomenclature have proven useful for autopsy practice and dementia research. However, some issues remain unresolved, such as cases with unusual features that do not fit with current diagnostic categories. The goal of this report is to update the neuropathologic criteria for the diagnosis and staging of LATE-NC, based primarily on published data. We provide practical suggestions about how to integrate available genetic information and comorbid pathologies [e.g., Alzheimer’s disease neuropathologic changes (ADNC) and Lewy body disease]. We also describe recent research findings that have enabled more precise guidance on how to differentiate LATE-NC from other subtypes of TDP-43 pathology [e.g., frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS)], and how to render diagnoses in unusual situations in which TDP-43 pathology does not follow the staging scheme proposed in 2019. Specific recommendations are also made on when not to apply this diagnostic term based on current knowledge. Neuroanatomical regions of interest in LATE-NC are described in detail and the implications for TDP-43 immunohistochemical results are specified more precisely. We also highlight questions that remain unresolved and areas needing additional study. In summary, the current work lays out a number of recommendations to improve the precision of LATE-NC staging based on published reports and diagnostic experience., We acknowledge National Institutes of Health Grants P30 AG072958 (S.-H. J.W.), P30 AG072977 (M.E.F.), K08 AG065463 (M.E.F.), RF1 AG072080 (M.E.F.), K08 AG 065426 (C.S.L), R01 AG038651 (E.L.A.), UF1 AG057707 (T.J.M and L.W), R01 AG021055 (C.K. & M.C.), P30 AG066519 (UCI ADRC), R01 AG061111 (P.T.N.), R01 AG057187 (P.T.N.), P30 AG072946 (P.T.N.), RF1 NS118584 (M.D.C.), P01 AG066597 (E.B.L.), P30 AG072979 (E.B.L.), U19 AG062418 (E.B.L.), P30 AG072959 (Cleveland ADRC), R01 AG062706 (S.A.S.), R01 AG054449 (M.E.M.), R01 AG075802 (M.E.M.), P30 AG 066507 (J.T.), U19 AG033655 (J.T.), RF1 AG069052 (J.G.R), P30 AG072972 (UC Davis ADRC), U19 AG069701 (M.E.M.), K24 AG053435 (L.T.G.), R01 AG067482 (J.A.S.), R01 AG064233 (J.A.S.), R01 AG022018 (J.A.S.), P30 AG010161/P30 AG072975 (J.A.S.), R01 AG064233 (K.A.), U01 AG061357 (B.N.D.), R01 AG052132 (B.N.D.), R01 AG056519 (B.N.D.), R01 AG062517 (B.N.D.), a research grant from the California Department Of Public Health (19-10611) with partial funding from the 2019 California Budget Act (B.N.D.), K23 AG062750 (H.-S. Y.), U19 AG024904 (K.E.S.), R21 AG078538 (K.E.S.), P30 AG 010133 (B.G. and K.N.), P30 AG062677 (Mayo ADRC), P30 AG066512 (T.W.), UF1 NS125417 (R.C.P.), U01 AG006786 (MCSA), R01 AG034676 (REP), P30 AG066509 (UW ADRC), and U19 AG066567 (ACT Study). Academy of Finland (341007) (L.M.); State funding for university-level health research (TYH2020231, TYH2022316) (L.M.); Liv och Hälsa Foundation (L.M.); Rossy Foundation and the Edmond Safra Philanthropic Foundation (G.G.K.); NOMIS foundation and Alzheimer Forschung Initiative (#21004) (M.N.); and, (#13803) (D.R.T.); UK Medical Research Council (MRC) (MRC/G9901400, U.1052.00.0013, G0900582). Addenbrooke’s Charitable Trust (S.H.), Addenbrooke’s Charitable Trust Grant 900108 (S.H.), Paul G. Allen Foundation (S.H.), ARUK NSG (S.H.), Alzheimer’s Society 554 (AS-PG-2019b-024) (S.H.), and the Nancy and Buster Alvord Endowment (C.D.K.). The Cambridge Brain Bank Laboratory is supported by the National Institute for Health Research, Cambridge Biomedical Research Centre. UK ARUK-PhD2014-19 (S.R.K.H.). Fonds Wetenschappelijk Onderzoek Vlaanderen (FWO: G0F8516N, G065721N) (D.R.T.); Stichting Alzheimer Onderzoek België (SAO-FRA: 2020/017) (D.R.T.); KU-Leuven Internal Funds (Belgium) (C14/17/107; C14/22/132; C3/20/057) (D.R.T.), (PDMT2/21/069) (S.O.T.); BrightFocus Foundation (A2022019F) (S.O.T.). “Miguel Servet” program (CP19/00031) (M.J.G.) and a research grant (PI20/00613) (M.J.G.) of the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER). Alzheimer’s Society (AS-JF-18-01; K.M.). Society for the Promotion of Research in Experimental Neurology, Vienna, Austria (K.J.)/Alzheimer’s Research UK (ARUK) doctoral studentship (ARUK-PhD2017-34) (R.M.). AMED under Grant Number JP22wm0425019 (to Y.S.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MRI-based basal forebrain atrophy and volumetric signatures associated with limbic TDP-43 compared to Alzheimer's disease pathology

  • Teipel, Stefan J.
  • Grothe, Michel J.
  • The Alzheimer's Disease Neuroimaging Initiative
© 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/)., [Background] It is not clear to which degree limbic TDP-43 pathology associates with a cholinergic deficit in the absence of Alzheimer's disease (AD) pathology., [Objective] Replicate and extend recent evidence on cholinergic basal forebrain atrophy in limbic TDP-43 and evaluate MRI based patterns of atrophy as a surrogate marker for TDP-43., [Methods] We studied ante-mortem MRI data of 11 autopsy cases with limbic TDP-43 pathology, 47 cases with AD pathology, and 26 mixed AD/TDP-43 cases from the ADNI autopsy sample, and 17 TDP-43, 170 AD, and 58 mixed AD/TDP-43 cases from the NACC autopsy sample. Group differences in basal forebrain and other brain volumes of interest were assessed using Bayesian ANCOVA. We assessed the diagnostic utility of MRI based patterns of brain atrophy using voxel-based receiver operating characteristics and random forest analyses., [Results] In the NACC sample, we found moderate evidence for the absence of a difference in basal forebrain volumes between AD, TDP-43, and mixed pathologies (Bayes factor(BF)10 = 0.324), and very strong evidence for lower hippocampus volume in TDP-43 and mixed cases compared with AD cases (BF10 = 156.1). The ratio of temporal to hippocampus volume reached an AUC of 75% for separating pure TDP-43 from pure AD cases. Random-forest analysis between TDP-43, AD, and mixed pathology reached only a multiclass AUC of 0.63 based on hippocampus, middle-inferior temporal gyrus, and amygdala volumes. Findings in the ADNI sample were consistent with these results., [Conclusion] A comparable degree of basal forebrain atrophy in pure TDP-43 cases compared to AD cases encourages studies on the effect of cholinergic treatment in amnestic dementia due to TDP-43. A distinct pattern of temporo-limbic brain atrophy may serve as a surrogate marker to enrich samples in clinical trials for the presence of TDP-43 pathology., MJG is supported by the “Miguel Servet” Program [CP19/00031] and a research grant [PI20/00613] of the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER), Spain. Part of the data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease

  • Muñoz-Delgado, Laura
  • Labrador, Miguel Ángel
  • Macías García, Daniel
  • Jesús Maestre, Silvia
  • Benítez Zamora, Belén
  • Fernández-Rodríguez, Paula
  • Adarmes-Gómez, Astrid
  • Reina-Castillo, María Isabel
  • Castro-Labrador, Sandra
  • Silva-Rodríguez, Jesús
  • Carrillo, Fátima
  • García-Solís, David
  • Grothe, Michel J.
  • Mir, Pablo
© 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., [Background] Peripheral inflammatory immune responses are suggested to play a major role in dopaminergic degeneration in Parkinson's disease (PD). The neutrophil-to-lymphocyte ratio (NLR) is a well-established biomarker of systemic inflammation in PD. Degeneration of the nigrostriatal dopaminergic system can be assessed in vivo using [123I]FP-CIT single photon emission computed tomography imaging of striatal dopamine transporter (DAT) density., [Objectives] To assess the relationship between the peripheral immune profile (NLR, lymphocytes, and neutrophils) and striatal DAT density in patients with PD., [Methods] We assessed clinical features, the peripheral immune profile, and striatal [123I]FP-CIT DAT binding levels of 211 patients with PD (primary-cohort). Covariate-controlled associations between the immune response and striatal DAT levels were assessed using linear regression analyses. For replication purposes, we also studied a separate cohort of 344 de novo patients with PD enrolled in the Parkinson's Progression Markers Initiative (PPMI-cohort)., [Results] A higher NLR was significantly associated with lower DAT levels in the caudate (primary-cohort: β = −0.01, p < 0.001; PPMI-cohort: β = −0.05, p = 0.05) and the putamen (primary-cohort: β = −0.05, p = 0.02; PPMI-cohort: β = −0.06, p = 0.02). Intriguingly, a lower lymphocyte count was significantly associated with lower DAT levels in both the caudate (primary-cohort: β = +0.09, p < 0.05; PPMI-cohort: β = +0.11, p = 0.02) and the putamen (primary-cohort: β = +0.09, p < 0.05, PPMI-cohort: β = +0.14, p = 0.01), but an association with the neutrophil count was not consistently observed (caudate; primary-cohort: β = −0.05, p = 0.02; PPMI-cohort: β = 0, p = 0.94; putamen; primary-cohort: β = −0.04, p = 0.08; PPMI-cohort: β = −0.01, p = 0.73)., [Conclusions] Our findings across two independent cohorts suggest a relationship between systemic inflammation and dopaminergic degeneration in patients with PD. This relationship was mainly driven by the lymphocyte count. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society., Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía. Grant Numbers: CTS-7685, CVI-02526, Consejería de Salud y Bienestar Social de la Junta de Andalucía. Grant Numbers: PE-0186-2019, PE-0210-2018, PI-0459-2018, PI-0471-2013, Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía. Grant Number: PY20_00896, Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER). Grant Numbers: PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Severe cholinergic terminal loss in newly diagnosed dementia with Lewy bodies

  • Okkels, Niels
  • Horsager, Jacob
  • Labrador, Miguel Ángel
  • Kjeldsen, Pernille L.
  • Damholdt, Malene F.
  • Mortensen, Janne
  • Vestergård, Karsten
  • Knudsen, Karoline
  • Andersen, Katrine B.
  • Fedorova, Tatyana D.
  • Skjærbæk, Casper
  • Gottrup, Hanne
  • Hansen, Allan K.
  • Grothe, Michel J.
  • Borghammer, Per
Cholinergic changes play a fundamental role in the natural history of dementia with Lewy bodies and Lewy body disease in general. Despite important achievements in the field of cholinergic research, significant challenges remain. We conducted a study with four main objectives: (i) to examine the integrity of cholinergic terminals in newly diagnosed dementia with Lewy bodies; (ii) to disentangle the cholinergic contribution to dementia by comparing cholinergic changes in Lewy body patients with and without dementia; (iii) to investigate the in vivo relationship between cholinergic terminal loss and atrophy of cholinergic cell clusters in the basal forebrain at different stages of Lewy body disease; and (iv) to test whether any asymmetrical degeneration in cholinergic terminals would correlate with motor dysfunction and hypometabolism. To achieve these objectives, we conducted a comparative cross-sectional study of 25 newly diagnosed dementia with Lewy bodies patients (age 74 ± 5 years, 84% male), 15 healthy control subjects (age 75 ± 6 years, 67% male) and 15 Parkinson's disease patients without dementia (age 70 ± 7 years, 60% male). All participants underwent 18F-fluoroetoxybenzovesamicol PET and high-resolution structural MRI. In addition, we collected clinical 18F-fluorodeoxyglucose PET images. Brain images were normalized to standard space and regional tracer uptake and volumetric indices of basal forebrain degeneration were extracted. Patients with dementia showed spatially distinct reductions in cholinergic terminals across the cerebral cortex, limbic system, thalamus and brainstem. Also, cholinergic terminal binding in cortical and limbic regions correlated quantitatively and spatially with atrophy of the basal forebrain. In contrast, patients without dementia showed decreased cholinergic terminal binding in the cerebral cortex despite preserved basal forebrain volumes. In patients with dementia, cholinergic terminal reductions were most severe in limbic regions and least severe in occipital regions compared to those without dementia. Interhemispheric asymmetry of cholinergic terminals correlated with asymmetry of brain metabolism and lateralized motor function. In conclusion, this study provides robust evidence for severe cholinergic terminal loss in newly diagnosed dementia with Lewy bodies, which correlates with structural imaging measures of cholinergic basal forebrain degeneration. In patients without dementia, our findings suggest that loss of cholinergic terminal function occurs ‘before’ neuronal cell degeneration. Moreover, the study supports that degeneration of the cholinergic system is important for brain metabolism and may be linked with degeneration in other transmitter systems. Our findings have implications for understanding how cholinergic system pathology contributes to the clinical features of Lewy body disease, changes in brain metabolism and disease progression patterns., Aase og Ejnar Danielsens fond (36456) (J.H.); ‘Miguel Servet’ program (CP19/00031) (M.G.); Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (PI20/00613) (M.G.); Lundbeck foundation (R-359-2020-2533) (P.B.); Michael J Fox Foundation (MJFF-022856) (P.B.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Structural and molecular cholinergic imaging markers of cognitive decline in Parkinson’s disease

  • Schumacher, Julia
  • Kanel, Prabesh
  • Dyrba, Martin
  • Storch, Alexander
  • Bohnen, Nicolaas I.
  • Teipel, Stefan J.
  • Grothe, Michel J.
Cognitive decline in Parkinson’s disease is related to cholinergic system degeneration, which can be assessed in vivo using structural MRI markers of basal forebrain volume and PET measures of cortical cholinergic activity. In the present study we aimed to examine the interrelation between basal forebrain degeneration and PET-measured depletion of cortical acetylcholinesterase activity as well as their relative contribution to cognitive impairment in Parkinson’s disease. This cross-sectional study included 143 Parkinson’s disease participants without dementia and 52 healthy control participants who underwent structural MRI, PET scanning with 11C-methyl-4-piperidinyl propionate (PMP) as a measure of cortical acetylcholinesterase activity, and a detailed cognitive assessment. Based on the fifth percentile of the overall cortical PMP PET signal from the control group, people with Parkinson’s disease were subdivided into a normo-cholinergic (n = 94) and a hypo-cholinergic group (n = 49). Volumes of functionally defined posterior and anterior basal forebrain subregions were extracted using an established automated MRI volumetry approach based on a stereotactic atlas of cholinergic basal forebrain nuclei. We used Bayesian t-tests to compare basal forebrain volumes between controls, and normo- and hypo-cholinergic Parkinson’s participants after covarying out age, sex and years of education. Associations between the two cholinergic imaging measures were assessed across all people with Parkinson’s disease using Bayesian correlations and their respective relations with performance in different cognitive domains were assessed with Bayesian ANCOVAs. As a specificity analysis, hippocampal volume was added to the analysis. We found evidence for a reduction of posterior basal forebrain volume in the hypo-cholinergic compared to both normo-cholinergic Parkinson’s disease [Bayes factor against the null model (BF10) = 8.2] and control participants (BF10 = 6.0), while for the anterior basal forebrain the evidence was inconclusive (BF10 < 3). In continuous association analyses, posterior basal forebrain volume was significantly associated with cortical PMP PET signal in a temporo-posterior distribution. The combined models for the prediction of cognitive scores showed that both cholinergic markers (posterior basal forebrain volume and cortical PMP PET signal) were independently related to multi-domain cognitive deficits, and were more important predictors for all cognitive scores, including memory scores, than hippocampal volume. We conclude that degeneration of the posterior basal forebrain in Parkinson’s disease is accompanied by functional cortical changes in acetylcholinesterase activity and that both PET and MRI cholinergic imaging markers are independently associated with multi-domain cognitive deficits in Parkinson’s disease without dementia. Comparatively, hippocampal atrophy only seems to have minimal involvement in the development of early cognitive impairment in Parkinson’s disease., This work was supported by NIH grants NS015655, NS091856, NS12306, and AG073100. M.J.G. is supported by the ‘Miguel Servet’ program [CP19/00031] and a research grant [PI20/00613] of the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome

  • Aranha, Mateus Rozalem
  • Iulita, Maria Florencia
  • Montal, Victor
  • Pegueroles, Jordi
  • Bejanin, Alexandre
  • Vaqué-Alcázar, Lídia
  • Grothe, Michel J.
  • Carmona-Iragui, Maria
  • Videla, Laura
  • Benejam, Bessy
  • Arranz, Javier
  • Padilla, Concepción
  • Valldeneu, Sílvia
  • Barroeta, Isabel
  • Altuna, Miren
  • Fernández, Susana
  • Ribas, Laia
  • Valle-Tamayo, Natalia
  • Alcolea, Daniel
  • González-Ortiz, Sofía
  • Bargalló, Núria
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Blesa, Rafael
  • Wisniewski, Thomas
  • Busciglio, Jorge
  • Cuello, A. Claudio
  • Lleó, Alberto
  • Fortea, Juan
[Background] Basal forebrain (BF) degeneration occurs in Down syndrome (DS)-associated Alzheimer's disease (AD). However, the dynamics of BF atrophy with age and disease progression, its impact on cognition, and its relationship with AD biomarkers have not been studied in DS., [Methods] We included 234 adults with DS (150 asymptomatic, 38 prodromal AD, and 46 AD dementia) and 147 euploid controls. BF volumes were extracted from T-weighted magnetic resonance images using a stereotactic atlas in SPM12. We assessed BF volume changes with age and along the clinical AD continuum and their relationship to cognitive performance, cerebrospinal fluid (CSF) and plasma amyloid/tau/neurodegeneration biomarkers, and hippocampal volume., [Results] In DS, BF volumes decreased with age and along the clinical AD continuum and significantly correlated with amyloid, tau, and neurofilament light chain changes in CSF and plasma, hippocampal volume, and cognitive performance., [Discussion] BF atrophy is a potentially valuable neuroimaging biomarker of AD-related cholinergic neurodegeneration in DS., This study was supported by the Fondo de Investigaciones Sanitario, Carlos III Health Institute (PI20/01473 to JF, PI13/01532, PI16/01825 to RB, PI18/00335 to MCI, PI18/00435 to DA, PI14/1561, PI20/01330 to AL, PI20/00613 to MJG) and the CIBERNED Program 1. This work was also supported by the National Institutes of Health (NIH) grants (1R01AG056850-01A1; 3RF1AG056850-01S1; AG056850, R21AG056974, and R01AG061566 to JF; P30AG066512 and P01AG060882 to TW), Departament de Salut de la Generalitat de Catalunya, Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151 to JF), and the European Union's Horizon 2020, ‘MES-CoBraD’ (H2020-SC1-BHC-2018-2020 / GA 965422 to JF). MRA acknowledges support from the Alzheimer's Association Research Fellowship to Promote Diversity (AARF-D) Program (AARFD-21-852492). MFI acknowledges support from the Jérôme Lejeune postdoctoral award and pilot grant (#1941). AB acknowledges support from a Miguel Servet grant (CP20/00038) from the Carlos III Health Institute. MJG acknowledges support from a Miguel Servet grant (CP19/00031) from the Carlos III Health Institute. MCI acknowledges support from the Alzheimer's Association and Global Brain Health Institute (GBHI_ALZ-18-543740), the Jérôme Lejeune Foundation (#1913 Cycle 2019B), and the Societat Catalana de Neurologia (Premi Beca Fundació SCN 2020). LVA was supported by Margarita Salas junior postdoctoral fellowship (UNI/551/2021, NextGenerationUE). VM and NVT acknowledge support from predoctoral grants from the Carlos III Health Institute (FI18/00275 to VM and FI22/00077 to NVT). MA and JA were supported by the Río Hortega Fellowship from Carlos III Health Institute (CM19/00066 to MA and CM21/00243 to JA). CP acknowledges support from a Sara Borrell Fellowship (CP20/00133) from the Carlos III Health Institute. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712 and #101053962), Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017-00915), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), and the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Longitudinal trajectories of cognitive reserve in hypometabolic subtypes of Alzheimer's disease

  • Levin, Fedor
  • Grothe, Michel J.
  • Dyrba, Martin
  • Franzmeier, Nicolai
  • Teipel, Stefan J.
  • Alzheimer’s Disease Neuroimaging Initiative
© 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)., Previous studies have demonstrated resilience to AD-related neuropathology in a form of cognitive reserve (CR). In this study we investigated a relationship between CR and hypometabolic subtypes of AD, specifically the typical and the limbic-predominant subtypes. We analyzed data from 59 Aβ-positive cognitively normal (CN), 221 prodromal Alzheimer’s disease (AD) and 174 AD dementia participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) from ADNI and ADNIGO/2 phases. For replication, we analyzed data from 5 Aβ-positive CN, 89 prodromal AD and 43 AD dementia participants from ADNI3. CR was estimated as standardized residuals in a model predicting cognition from temporoparietal grey matter volumes and covariates. Higher CR estimates predicted slower cognitive decline. Typical and limbic-predominant hypometabolic subtypes demonstrated similar baseline CR, but the results suggested a faster decline of CR in the typical subtype. These findings support the relationship between subtypes and CR, specifically longitudinal trajectories of CR. Results also underline the importance of longitudinal analyses in research on CR., MJG is supported by the "Miguel Servet" program [CP19/00031] and a research grant [PI20/00613] of the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Impaired cholinergic integrity of the colon and pancreas in dementia with Lewy bodies

  • Okkels, Niels
  • Horsager, Jacob
  • Fedorova, Tatyana D.
  • Knudsen, Karoline
  • Skjærbæk, Casper
  • Andersen, Katrine B.
  • Labrador-Espinosa, Miguel
  • Vestergård, Karsten
  • Mortensen, Janne
  • Klit, Henriette
  • Møller, Mette
  • Danielsen, Erik H.
  • Johnsen, Erik L.
  • Bekan, Goran
  • Hansen, Kim V.
  • Munk, Ole L.
  • Damholdt, Malene F.
  • Kjeldsen, Pernille L.
  • Hansen, Allan K.
  • Gottrup, Hanne
  • Grothe, Michel J.
  • Borghammer, Per
Dementia with Lewy bodies is characterized by a high burden of autonomic dysfunction and Lewy pathology in peripheral organs and components of the sympathetic and parasympathetic nervous system. Parasympathetic terminals may be quantified with 18F-fluoroetoxybenzovesamicol, a PET tracer that binds to the vesicular acetylcholine transporter in cholinergic presynaptic terminals. Parasympathetic imaging may be useful for diagnostics, improving our understanding of autonomic dysfunction and for clarifying the spatiotemporal relationship of neuronal degeneration in prodromal disease. Therefore, we aimed to investigate the cholinergic parasympathetic integrity in peripheral organs and central autonomic regions of subjects with dementia with Lewy bodies and its association with subjective and objective measures of autonomic dysfunction. We hypothesized that organs with known parasympathetic innervation, especially the pancreas and colon, would have impaired cholinergic integrity. To achieve these aims, we conducted a cross-sectional comparison study including 23 newly diagnosed non-diabetic subjects with dementia with Lewy bodies (74 ± 6 years, 83% male) and 21 elderly control subjects (74 ± 6 years, 67% male). We obtained whole-body images to quantify PET uptake in peripheral organs and brain images to quantify PET uptake in regions of the brainstem and hypothalamus. Autonomic dysfunction was assessed with questionnaires and measurements of orthostatic blood pressure. Subjects with dementia with Lewy bodies displayed reduced cholinergic tracer uptake in the pancreas (32% reduction, P = 0.0003) and colon (19% reduction, P = 0.0048), but not in organs with little or no parasympathetic innervation. Tracer uptake in a region of the medulla oblongata overlapping the dorsal motor nucleus of the vagus correlated with autonomic symptoms (rs = −0.54, P = 0.0077) and changes in orthostatic blood pressure (rs = 0.76, P < 0.0001). Tracer uptake in the pedunculopontine region correlated with autonomic symptoms (rs = −0.52, P = 0.0104) and a measure of non-motor symptoms (rs = −0.47, P = 0.0230). In conclusion, our findings provide the first imaging-based evidence of impaired cholinergic integrity of the pancreas and colon in dementia with Lewy bodies. The observed changes may reflect parasympathetic denervation, implying that this process is initiated well before the point of diagnosis. The findings also support that cholinergic denervation in the brainstem contributes to dysautonomia., M.J.G. is supported by a research grant of the Instituto de Salud Carlos III - Fondo Europeo de Desarrollo Regional (PI20/00613) and the ‘Miguel Servet’ program (CP19/00031). J.H. is supported by Aase og Ejnar Danielsens fond (36456). P.B. is supported by grants from the Michael J. Fox Foundation (MJFF-022856) and Lundbeck foundation (R-359-2020-2533)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

"Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson's disease"

  • Muñoz-Delgado, Laura
  • Williams-Gray, Caroline H.
  • Garraux, Gaetan
  • Clemente, Diego
  • Öztop-Çakmak, Özgür
  • Greenland, Julia C.
  • Figueira, Inês
  • Machín-Díaz, Isabel
  • Pirovano, Elenamaria
  • Di Flora, Alessia
  • Tournerie, Clotilde
  • Papoutsopoulou, Stamatia
  • Ertan, Sibel
  • Mir, Pablo
  • Comi, Cristoforo
Growing evidence supports the importance of immune processes in Parkinson’s disease (PD). However, there is a need to improve the quality of observational clinical studies investigating the role of immunity in PD. In this context, an expert panel from the COST Action IMMUPARKNET (CA21117) aimed to develop guidance recommendations for conducting optimal immune profiling in PD. Firstly, criteria for inclusion and exclusion of participants, clinical data collection and participant stratification have been considered. Secondly, brain imaging of neuroinflammation has been reviewed. Finally, this review discusses sample collection, handling and storage of biological samples. In conclusion, this document aims to guide the scientific community in the optimal design of immune profiling studies in PD, so that we can generate robust and reliable data to advance our knowledge in this field., This publication is based upon work from COST Action CA21117, The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork [IMMUPARKNET], supported by COST (European Cooperation in Science and Technology) (www.cost.eu). Laura Muñoz-Delgado is financially supported by the “Juan Rodés” programme (JR23/00016) from the Instituto de Salud Carlos III and receives funding support from the Consejería de Salud y Consumo de la Junta de Andalucía (NEU-0005-2022). Caroline Williams-Grey receives financial support from the NIHR Cambridge Biomedical Research Centre (NIHR203312) and the Cambridge Centre for Parkinson-Plus, and grant funding from the UKRI Medical Research Council (MR/W029235/1), Cure Parkinson’s, Parkinson’s UK, and the Rosetrees Trust. Gaetan Garraux is supported by ‘Fonds Rahier’, University of Liège and Fonds de la Recherche Scientifique (F.R.S.-FNRS) de Belgique. Gaëtan Garraux has also received support for travel or honorarium from AbbVie, Eurogenerics and Zambon. Diego Clemente has received funding support from Instituto de Salud Carlos III (PI18/00357, PI21/00302, PI24/00447, co-funded by the European Union, CIBERNED CB22/05/00016, “INVESTIGO” programme in the frame of the Plan para la Recuperación, Transformación y Resiliencia (European Union Next Generation funds), and EMD Serono R&D Agreement). Ines Figueira is supported by the the ERC—Grant No. 804229; through PeX—2022.02127.PTDC (PERCEPT) and through the R&D unit iNOVA4Health (LISBOA-01-0145-FEDER-007344; UIDB/04462/2020), and LS4FUTURE Associated Laboratory (LA/P/0087/2020).Pablo Mir has received financial support from the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704 and PI23/00512), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685), the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018 and PE-0186-2019), the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00896). Pablo Mir has also received support for attending meetings and/or travel or honorarium for lecturing from Abbott, Allergan, AbbVie, Bial, Britannia, Italfarmaco, Merz, UCB, Teva and Zambon. Cristoforo Comi is supported by the AGING PROJECT—Department of Excellence—Università del Piemonte Orientale. Cristoforo Comi has received travel grants for meeting participation from Ecupharma, Bial and Novartis., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Role of POLE and POLD1 in familial cancer

  • Mur, Pilar
  • García-Mulero, Sandra
  • Vidal, August
  • Balmaña Gelpí, Judith
  • Pineda, Marta
  • del Valle, Jesús
  • Magraner-Pardo, Lorena
Domini de l'exonucleasa; Càncer colorectal hereditari; Fenotip ultramutat, Dominio exonucleasa; Cáncer colorrectal hereditario; Fenotipo ultramutado, Exonuclease domain; Hereditary colorectal cancer; Ultramutated phenotype, Purpose Germline pathogenic variants in the exonuclease domain (ED) of polymerases POLE and POLD1 predispose to adenomatous polyps, colorectal cancer (CRC), endometrial tumors, and other malignancies, and exhibit increased mutation rate and highly specific associated mutational signatures. The tumor spectrum and prevalence of POLE and POLD1 variants in hereditary cancer are evaluated in this study. Methods POLE and POLD1 were sequenced in 2813 unrelated probands referred for genetic counseling (2309 hereditary cancer patients subjected to a multigene panel, and 504 patients selected based on phenotypic characteristics). Cosegregation and case–control studies, yeast-based functional assays, and tumor mutational analyses were performed for variant interpretation. Results Twelve ED missense variants, 6 loss-of-function, and 23 outside-ED predicted-deleterious missense variants, all with population allele frequencies <1%, were identified. One ED variant (POLE p.Met294Arg) was classified as likely pathogenic, four as likely benign, and seven as variants of unknown significance. The most commonly associated tumor types were colorectal, endometrial and ovarian cancers. Loss-of-function and outside-ED variants are likely not pathogenic for this syndrome. Conclusions Polymerase proofreading–associated syndrome constitutes 0.1–0.4% of familial cancer cases, reaching 0.3–0.7% when only CRC and polyposis are considered. ED variant interpretation is challenging and should include multiple pieces of evidence., We thank Gemma Aiza, Mireia Menéndez, Sara González, and Xavier Muñoz for support, and Biobanc HUB-ICO-IDIBELL, integrated in the Spanish Platform Biobanks Network and funded by Instituto de Salud Carlos III (PT17/0015/0024) and Xarxa Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya. This work was funded by the Spanish Ministry of Science and Innovation, cofunded by FEDER funds (SAF2016-80888-R, SAF2015-68016-R, Severo Ochoa SVP-2014-068895 contract [L.M.-P.]); Instituto de Salud Carlos III (PI16/00563, PI16/00588, PI14/00613, PI19/00553, CIBERONC CB16/12/00234, CIBERESP, Sara Borrell contract [P.M.]); Government of Catalonia [AGAUR 2017SGR1282, CERCA Program]; and Fundación Olga Torres. This study was facilitated by COST Action CA17118, supported by COST (European Cooperation in Science and Technology).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Risk Model for Prostate Cancer Using Environmental and Genetic Factors in the Spanish Multi-Case- Control (MCC) Study

  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Fernández-Navarro, Pablo|||0000-0001-9427-2581
  • Palazuelos, Camilo
  • Morros, Rosa|||0000-0001-6752-8748
  • Aragonés, Nuria
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Jiménez Monleón, Jose J.
  • Ruiz Cerdá, José Luis
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Ruiz-Dominguez, José Manuel
  • Alonso Molero, Jessica|||0000-0002-1939-8798
  • Pollán, Marina|||0000-0002-4328-1565
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Llorca, Javier|||0000-0001-8569-861X
Prostate cancer (PCa) is the second most common cancer among men worldwide. Its etiology remains largely unknown compared to other common cancers. We have developed a risk stratification model combining environmental factors with family history and genetic susceptibility. 818 PCa cases and 1,006 healthy controls were compared. Subjects were interviewed on major lifestyle factors and family history. Fifty-six PCa susceptibility SNPs were genotyped. Risk models based on logistic regression were developed to combine environmental factors, family history and a genetic risk score. In the whole model, compared with subjects with low risk (reference category, decile 1), those carrying an intermediate risk (decile 5) had a 265% increase in PCa risk (OR = 3.65, 95% CI 2.26 to 5.91). The genetic risk score had an area under the ROC curve (AUROC) of 0.66 (95% CI 0.63 to 0.68). When adding the environmental score and family history to the genetic risk score, the AUROC increased by 0.05, reaching 0.71 (95% CI 0.69 to 0.74). Genetic susceptibility has a stronger risk value of the prediction that modifiable risk factors. While the added value of each SNP is small, the combination of 56 SNPs adds to the predictive ability of the risk model.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Statin use and the risk of colorectal cancer in a population-based electronic health records study

  • Ibáñez-Sanz, Gemma|||0000-0001-6071-7343
  • Guinó, Elisabet|||0000-0003-0093-2652
  • Pontes García, Caridad|||0000-0002-3274-6048
  • Quijada-Manuitt, María Ángeles|||0000-0002-9624-0177
  • de la Peña, Luisa|||0000-0002-8496-3415
  • Aragón, María|||0000-0002-5990-6953
  • Domínguez, Marga
  • Rodríguez-Alonso, Lorena
  • Blasco, Alex
  • García-Rodríguez, Ana
  • Morros, Rosa|||0000-0001-6752-8748
There is extensive debate regarding the protective effect of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) on colorectal cancer (CRC). We aimed to assess the association between CRC risk and exposure to statins using a large cohort with prescription data. We carried out a case-control study in Catalonia using the System for Development of Primary Care Research (SIDIAP) database that recorded patient diseases history and linked data on reimbursed medication. The study included 25 811 cases with an incident diagnosis of CRC between 2010 and 2015 and 129 117 frequency-matched controls. Subjects were classified as exposed to statins if they had ever been dispensed statins. Analysis considering mean daily defined dose, cumulative duration and type of statin were performed. Overall, 66 372 subjects (43%) were exposed to statins. There was no significant decrease of CRC risk associated to any statin exposure (OR = 0.98; 95% CI: 0.95-1.01). Only in the stratified analysis by location a reduction of risk for rectal cancer was observed associated to statin exposure (OR = 0.87; 95% CI: 0.81-0.92). This study does not support an overall protective effect of statins in CRC, but a protective association with rectal cancer merits further research.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tumour characteristics and survivorship in a cohort of breast cancer, the MCC-Spain study

  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Palazuelos-Calderón, Camilo
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Amiano, Pilar
  • Guevara, Marcela|||0000-0001-9242-6364
  • Molina de la Torre, Antonio José
  • Domingo, Laia|||0000-0003-4420-0891
  • Fernández-Ortiz, María|||0000-0003-0017-875X
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Alguacil, Juan|||0000-0003-2703-9725
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Ibáñez, Josefa
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Diaz-Santos, Marian
  • Alonso, M. Henar
  • Alonso Molero, Jessica|||0000-0002-1939-8798
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • García Palomo, Andrés|||0000-0002-9159-9025
  • Ardanaz, Eva
  • Molinuevo, Amaia
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The objective of this study is to analyse the relative survival with breast cancer in women diagnosed after new treatments were generalised and to ascertain the current effect that tumour characteristics such as grade, stage or subtype have on survival as well as the new AJCC-pathological prognostic score. The breast cancer MCC-Spain follow-up study is a prospective cohort study of 1685 incident breast cancer cases. Women between 20 and 85 years old were recruited between the years 2008 and 2013 in 18 hospitals located in 10 Spanish provinces and they have been followed until 2017/2018. Relative survival was estimated after 3, 5 and 8 years of follow-up using Ederer II method. In addition, Weibull regression adjusted by age, hospital, grade and stage was used to investigate prognosis factors. Among components of TNM staging system, tumour size greater than 50 mm (i.e. T3 or T4) more than doubled the risk of dying, while N3 nodal involvement and presence of metastasis had a huge effect on mortality. The AJCC pathological prognostic score strongly correlated with survival; thus, hazard ratios increased as the score rose, being 2.31, 4.00, 4.94, 7.92, 2.26, 14.9 and 58.9 for scores IB, IIA, IIB, IIIA, IIIB, IIIC and IV, respectively. Both TNM staging and histological/molecular biomarkers are associated with overall survival in Spanish women with breast cancer; when both are combined in the AJCC pathological prognosis score, the prognostic value improved with risk indices that increased rapidly as the pathological prognosis score increased The online version of this article (10.1007/s10549-020-05600-x) contains supplementary material, which is available to authorised users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dietary Constituents, Relationship with Breast Cancer Prognostic (MCC-SPAIN Follow-Up)

  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Gutiérrez-Ruiz, Nuria
  • Aragonés, Nuria
  • Amiano, Pilar
  • Molina de la Torre, Antonio José
  • Guevara, Marcela|||0000-0001-9242-6364
  • Alonso Molero, Jessica|||0000-0002-1939-8798
  • Obón-Santacana, Mireia|||0000-0003-4646-3513
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Molina-Barceló, Ana|||0000-0001-5113-6475
  • Alguacil, Juan|||0000-0003-2703-9725
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Rodríguez-Cundín, Paz
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Canseco Fernandez, Rosario
  • Castilla, Jesus|||0000-0002-6396-7265
  • Molinuevo, Amaia
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The aim of this study was to characterize the relationship between the intake of the major nutrients and prognosis in breast cancer. A cohort based on 1350 women with invasive (stage I-IV) breast cancer (BC) was followed up. Information about their dietary habits before diagnosis was collected using a semi-quantitative Food Frequency Questionnaire. Participants without FFQ or with implausible energy intake were excluded. The total amount consumed of each nutrient (Kcal/day) was divided into tertiles, considering as "high intakes" those above third tertile. The main effect studied was overall survival. Cox regression was used to assess the association between death and nutrient intake. During a median follow-up of 6.5 years, 171 deaths were observed. None of the nutrients analysed was associated with mortality in the whole sample. However, in normal-weight women (BMI 18.5-25 kg/m 2) a high intake of carbohydrates (≥809 Kcal/day), specifically monosaccharides (≥468 Kcal/day), worsened prognostic compared to lowest (≤352 Kcal/day). Hazard Ratios (HRs) for increasing tertiles of intake were HR:2.22 95% CI (1.04 to 4.72) and HR:2.59 95% CI (1.04 to 6.48), respectively (p trend = 0.04)). Conversely, high intakes of polyunsaturated fats (≥135 Kcal/day) improved global survival (HR: 0.39 95% CI (0.15 to 1.02) p -trend = 0.05) compared to the lowest (≤92.8 kcal/day). In addition, a protective effect was found substituting 100 kcal of carbohydrates with 100 kcal of fats in normal-weight women (HR: 0.76 95% CI (0.59 to 0.98)). Likewise, in premenopausal women a high intake of fats (≥811 Kcal/day) showed a protective effect (HR:0.20 95% CI (0.04 to 0.98) p trend = 0.06). Finally, in Estrogen Receptors (ER) negative tumors, we found a protective effect of high intake of animal proteins (≥238 Kcal/day, HR: 0.24 95% CI (0.06 to 0.98). According to our results, menopausal status, BMI and ER status could play a role in the relationship between diet and BC survival and must be taken into account when studying the influence of different nutrients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease, Imaging results from the COPPADIS study

  • Grothe, Michel|||0000-0003-2600-9022
  • Labrador-Espinosa, Miguel A.|||0000-0003-3576-1777
  • Jesús Maestre, Silvia|||0000-0002-1874-4628
  • Macías-García, Daniel|||0000-0002-4822-1529
  • Adarmes-Gómez, A.D.|||0000-0002-1337-9289
  • Carrillo, Fátima
  • Iglesias Camacho, Elena
  • Franco-Rosado, Pablo
  • Roldán Lora, Florinda
  • Martín-Rodríguez, Juan Francisco|||0000-0003-1392-8775
  • Aguilar Barberà, Miquel
  • Pastor, Pau|||0000-0002-7493-8777
  • Escalante, Sonia|||0000-0001-8931-1400
  • Soriano Vila, Berta
  • Cots-Foraster, Anna|||0000-0002-9169-7653
  • Ruiz Martínez, Javier|||0000-0001-7326-6270
  • Carrillo Padilla, Francisco
  • Pueyo Morlans, Mercedes
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Infante Ceberio, Jon
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338
  • de Deus Fonticoba, Teresa
  • Pascual Sedano, Berta María|||0000-0002-9298-8241
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Santos García, Diego|||0000-0002-3126-5111
  • Mir, Pablo|||0000-0003-1656-302X
Introduction: We aimed to assess associations between multimodal neuroimaging measures of cholinergic basal forebrain (CBF) integrity and cognition in Parkinson's disease (PD) without dementia. Methods: The study included a total of 180 non-demented PD patients and 45 healthy controls, who underwent structural MRI acquisitions and standardized neurocognitive assessment through the PD-Cognitive Rating Scale (PD-CRS) within the multicentric COPPADIS-2015 study. A subset of 73 patients also had Diffusion Tensor Imaging (DTI) acquisitions. Volumetric and microstructural (mean diffusivity, MD) indices of CBF degeneration were automatically extracted using a stereotactic CBF atlas. For comparison, we also assessed multimodal indices of hippocampal degeneration. Associations between imaging measures and cognitive performance were assessed using linear models. Results: Compared to controls, CBF volume was not significantly reduced in PD patients as a group. However, across PD patients lower CBF volume was significantly associated with lower global cognition (PD-CRS: r = 0.37, p < 0.001), and this association remained significant after controlling for several potential confounding variables (p = 0.004). Analysis of individual item scores showed that this association spanned executive and memory domains. No analogue cognition associations were observed for CBF MD. In covariate-controlled models, hippocampal volume was not associated with cognition in PD, but there was a significant association for hippocampal MD (p = 0.02). Conclusions: Early cognitive deficits in PD without dementia are more closely related to structural MRI measures of CBF degeneration than hippocampal degeneration. In our multicentric imaging acquisitions, DTI-based diffusion measures in the CBF were inferior to standard volumetric assessments for capturing cognition-relevant changes in non-demented PD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome

  • Aranha, Mateus|||0000-0001-9594-292X
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Grothe, Michel|||0000-0003-2600-9022
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Padilla, Concepción|||0000-0003-4102-6787
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Fernández, Susana|||0000-0002-9777-1156
  • Ribas, Laia
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Alcolea, Daniel|||0000-0002-3819-3245
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Bargalló, Núria|||0000-0001-6284-5402
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Blesa, Rafael|||0000-0003-4026-2884
  • Wisniewski, Thomas M.
  • Busciglio, Jorge A.
  • Cuello, AC.|||0000-0003-2143-2745
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Background: Basal forebrain (BF) degeneration occurs in Down syndrome (DS)-associated Alzheimer's disease (AD). However, the dynamics of BF atrophy with age and disease progression, its impact on cognition, and its relationship with AD biomarkers have not been studied in DS. Methods: We included 234 adults with DS (150 asymptomatic, 38 prodromal AD, and 46 AD dementia) and 147 euploid controls. BF volumes were extracted from T-weighted magnetic resonance images using a stereotactic atlas in SPM12. We assessed BF volume changes with age and along the clinical AD continuum and their relationship to cognitive performance, cerebrospinal fluid (CSF) and plasma amyloid/tau/neurodegeneration biomarkers, and hippocampal volume. Results: In DS, BF volumes decreased with age and along the clinical AD continuum and significantly correlated with amyloid, tau, and neurofilament light chain changes in CSF and plasma, hippocampal volume, and cognitive performance. Discussion: BF atrophy is a potentially valuable neuroimaging biomarker of AD-related cholinergic neurodegeneration in DS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of POLE and POLD1 in familial cancer

  • Mur, Pilar
  • García-Mulero, Sandra|||0000-0003-4931-1267
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Magraner-Pardo, Lorena
  • Vidal, August|||0000-0001-5727-2099
  • Pineda, Marta|||0000-0002-5403-5845
  • Cinnirella, Giacomo
  • Martín-Ramos, Edgar
  • Pons, Tirso|||0000-0002-7616-7750
  • López-Doriga, Adriana
  • Belhadj, Sami|||0000-0002-0528-9187
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Munoz-Torres, Pau M.|||0000-0002-0168-3224
  • Navarro, Matilde
  • Grau, Elia
  • Darder, Esther
  • Llort, Gemma|||0000-0001-9987-7862
  • Sanz, Judit
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Brunet, Joan|||0000-0003-1945-3512
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Piulats, Josep M.|||0000-0002-3606-1724
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Sanz-Pamplona, Rebeca
  • Aligué, Rosa
  • Capella, Gabriel|||0000-0002-4669-7320
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Valle, Laura|||0000-0003-0371-0844
Germline pathogenic variants in the exonuclease domain (ED) of polymerases POLE and POLD1 predispose to adenomatous polyps, colorectal cancer (CRC), endometrial tumors, and other malignancies, and exhibit increased mutation rate and highly specific associated mutational signatures. The tumor spectrum and prevalence of POLE and POLD1 variants in hereditary cancer are evaluated in this study. POLE and POLD1 were sequenced in 2813 unrelated probands referred for genetic counseling (2309 hereditary cancer patients subjected to a multigene panel, and 504 patients selected based on phenotypic characteristics). Cosegregation and case-control studies, yeast-based functional assays, and tumor mutational analyses were performed for variant interpretation. Twelve ED missense variants, 6 loss-of-function, and 23 outside-ED predicted-deleterious missense variants, all with population allele frequencies <1%, were identified. One ED variant (POLE p.Met294Arg) was classified as likely pathogenic, four as likely benign, and seven as variants of unknown significance. The most commonly associated tumor types were colorectal, endometrial and ovarian cancers. Loss-of-function and outside-ED variants are likely not pathogenic for this syndrome. Polymerase proofreading-associated syndrome constitutes 0.1-0.4% of familial cancer cases, reaching 0.3-0.7% when only CRC and polyposis are considered. ED variant interpretation is challenging and should include multiple pieces of evidence.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Role of POLE and POLD1 in familial cancer

  • Mur, Pilar
  • García-Mulero, Sandra
  • Vidal, August
  • Balmaña Gelpí, Judith
  • Pineda, Marta
  • del Valle, Jesús
  • Magraner-Pardo, Lorena
Domini de l'exonucleasa; Càncer colorectal hereditari; Fenotip ultramutat, Dominio exonucleasa; Cáncer colorrectal hereditario; Fenotipo ultramutado, Exonuclease domain; Hereditary colorectal cancer; Ultramutated phenotype, Purpose Germline pathogenic variants in the exonuclease domain (ED) of polymerases POLE and POLD1 predispose to adenomatous polyps, colorectal cancer (CRC), endometrial tumors, and other malignancies, and exhibit increased mutation rate and highly specific associated mutational signatures. The tumor spectrum and prevalence of POLE and POLD1 variants in hereditary cancer are evaluated in this study. Methods POLE and POLD1 were sequenced in 2813 unrelated probands referred for genetic counseling (2309 hereditary cancer patients subjected to a multigene panel, and 504 patients selected based on phenotypic characteristics). Cosegregation and case–control studies, yeast-based functional assays, and tumor mutational analyses were performed for variant interpretation. Results Twelve ED missense variants, 6 loss-of-function, and 23 outside-ED predicted-deleterious missense variants, all with population allele frequencies <1%, were identified. One ED variant (POLE p.Met294Arg) was classified as likely pathogenic, four as likely benign, and seven as variants of unknown significance. The most commonly associated tumor types were colorectal, endometrial and ovarian cancers. Loss-of-function and outside-ED variants are likely not pathogenic for this syndrome. Conclusions Polymerase proofreading–associated syndrome constitutes 0.1–0.4% of familial cancer cases, reaching 0.3–0.7% when only CRC and polyposis are considered. ED variant interpretation is challenging and should include multiple pieces of evidence., We thank Gemma Aiza, Mireia Menéndez, Sara González, and Xavier Muñoz for support, and Biobanc HUB-ICO-IDIBELL, integrated in the Spanish Platform Biobanks Network and funded by Instituto de Salud Carlos III (PT17/0015/0024) and Xarxa Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya. This work was funded by the Spanish Ministry of Science and Innovation, cofunded by FEDER funds (SAF2016-80888-R, SAF2015-68016-R, Severo Ochoa SVP-2014-068895 contract [L.M.-P.]); Instituto de Salud Carlos III (PI16/00563, PI16/00588, PI14/00613, PI19/00553, CIBERONC CB16/12/00234, CIBERESP, Sara Borrell contract [P.M.]); Government of Catalonia [AGAUR 2017SGR1282, CERCA Program]; and Fundación Olga Torres. This study was facilitated by COST Action CA17118, supported by COST (European Cooperation in Science and Technology).